

Confidential

Filed on 31/3/2004

FLUORESCENTLY TAGGED LIGANDS

The present invention relates to a library of tagged non-peptide ligands comprising one or a plurality of ligand moieties each linked to one or a plurality of different tag moieties; a process for the preparation thereof; a method for the rational design of a library and selection from the library of a tagged ligand; a kit comprising reactive non-peptide ligand(s) and reactive tagging substrate(s) for the preparation of the library of tagged non-peptide ligands; tagged non-peptide ligands associated with information on their pharmacology; novel tagged ligands; novel ligand precursors and processes for the preparation thereof; the use of known and novel tagged ligands and libraries of tagged ligands in studying receptor binding such as G-protein coupled receptor (GPCR) binding or intracellular enzyme inhibition such as cyclic nucleotide phosphodiesterase inhibition and binding of drugs to drug transporters (eg nucleoside transporters or ATP binding cassette transporters); more specifically studying these interactions in cell populations or single cells such as acutely dispersed cells using techniques such as Confocal Microscopy and Fluorescence Activated Sorting and Fluorescence Correlation Microscopy.

The adenosine-A₁ receptor (A₁-AR) is a GPCR which is found in a variety of tissues including brain, heart, adipose tissue and muscle, and has been implicated in the pathophysiology of a number of conditions (Ralevic, V. and Burnstock, J (1998) Pharmacol. Rev. 50, 415).

Currently the study of A₁-AR pharmacology can only be performed well in cells which can be grown in large numbers using for example techniques such as radioligand binding. Autoradiography enables single cell studies but does not allow direct reading of binding and can take up to 4 - 6 weeks to develop the film to obtain results of binding. To overcome this problem, a very few fluorescent ligands have been adapted for use in visualising receptors and obtaining quantitative receptor-ligand binding data in single cells, using confocal microscopy (CSLM), confocal plate readers, fluorescence polarisation plate readers, and fluorescence correlation spectroscopy (FCS). Confocal microscopy allows visualisation of a section through a


cell, concentration of fluorophore at the cell edges indicates membrane receptor binding. FCS analyses the diffusion characteristics of fluorescent species, fast-diffusing free ligand can be distinguished from slowly-diffusing receptor-bound ligand and quantified simultaneously when the volume is localised to the cell 5 membrane.

McGrath *et al* *TiPS* November 1996 (Vol 17) 393 – 399 reviews the possibilities for using fluorescent ligands in place of more traditional radioactive ligands in the study of cell receptors to report the amount of ligand-receptor complex indicating the 10 number of receptors, using confocal spectroscopy and fluorescence activated cell sorting (FACS). He states that many attempts have been made at conjugating fluorescent molecules to receptor ligands in the hope of identifying their binding sites, aimed mainly at localisation of the receptors rather than studying their properties. Some compounds are reported that fluoresce when bound to a receptor 15 but which give low background noise in the aqueous phase. A reported objective was to produce a fluorescent drug which would remain fluorescent when bound to the receptor and would remain bound when unbound drug was washed away. Therefore there was a need for very high receptor binding affinity. Reviewed work includes fluorescent ligand binding to nicotinic receptors, beta adrenoceptors, opioid GPCR 20 type receptors, histamine, neurotensin and alpha-adrenoceptors. The publication also reviews benefits of confocal microscopy. Efforts made to study the pharmacological properties of the ligands are reported in only a few of the above cases.

However very few efforts to visualise receptors or classes of receptors have been 25 shown to work. Pharmacological properties are usually to some extent affected by linking of a fluorophore to any receptor binding ligand, and include change in binding affinity, and in activation or otherwise of receptor, ie agonist or antagonist properties. It is important that the pharmacology of the fluorescent ligand is known in any studies in order to quantify the binding results observed.

In fact the synthesis of non-peptide fluorescent ligands for GPCRs presents serious problems. The few commercial non peptide fluorescent ligands for cell surface receptors that have been synthesised include histamine-BODIPY™ FL and (pictured below) CGP12177-BODIPY™ TMR (Molecular Probes):

5



The BODIPY™ (BDI) fluorophores were initially designed for attaching to proteins which present a much more uniform prospect for attaching: kits are available comprising a fluorophore and a set of reagents for universally attaching to most proteins. These give non specific attachments to any reactive site on the protein of interest and usually there is no need to know the nature or location of the attachment.

10 However these proteins are larger molecules than the non-peptide ligands, including drugs such as XAC (xanthine amine congener) etc envisaged in the present invention. The ligand binding site for the many GPCR receptors is also usually deep within the transmembrane regions of the receptor and thus the challenge is to attach

15 to the fluorophore in such a way as to retain pharmacological activity. None of these BDI fluorophores are concerned with the specific design of fluorescent agonists/antagonists with defined properties at GPCR's but rather with the fluorophore as an "add-on" probe.

20 In summary therefore the availability of fluorescent ligands and in particular non-peptide fluorescent ligands suitable for FCS and CM binding studies is virtually non-existent. The preparation of such compounds is far from routine and few efforts have been made to establish pharmacology. McGrath above only looked at a few of the receptor types studied.

25

There is moreover no unified approach in much of the prior art. Individual research has addressed fluorescent ligand systems which are limited to specific drug classes and or to the use of specific fluorophores. Such systems are limiting in both the information which can be obtained and in the number of systems which can be
5 investigated.

Accordingly there is a need for novel selective fluorescent ligands for binding at desired receptors giving reliable and effective receptor visualisation and receptor selectivity with established pharmacology in terms of both affinity and agonist and
10 antagonist properties.

We have now applied a multidisciplinary approach to fluorescent ligand design to provide a library of rationally designed fluorescently tagged ligands and a process for preparation thereof that may be used in a method for selection of a fluorescently
15 tagged ligand which is selective to a desired GPCR, having required defined pharmacological characteristics.

The library is obtained from preferably non-peptide ligand precursors comprising chemical functionality for linking to any fluorophore to provide known or novel
20 fluorescent ligands with linking at a desired site enabling selection of a fluorescent ligand providing retention of receptor binding capability and linking in manner not to interfere with receptor binding capability, or to modify binding capability in known manner. The linker precursors may also provide improved properties such as water solubility, on linking to a fluorescent moiety or any other desired non-hydrophilic
25 probe.

In the broadest aspect of the invention there is provided a library comprising a plurality of tagged non-peptide ligands of formula I

30 $(Lig J_L)_m L (J_T Tag)_n (J_T L (J_L Lig)_p)_q$

including salts thereof

comprising one or a plurality of same or different ligand moieties Lig each linked to a one or a plurality of same or different tag moieties Tag via same or different linker moieties L and same or different linking site or linking functionality J_T and J_L wherein Lig comprises a GPCR ligand, an inhibitor of an intracellular enzyme or a substrate or inhibitor of a drug transporter;

5 L is a single bond or is any linking moiety selected from a heteroatom such as N, O, S, P, branched or straight chain saturated or unsaturated, optionally heteroatom containing, C₁₋₆₀₀ hydrocarbyl and combinations thereof, which may be monomeric, oligomeric having oligomeric repeat of 2 to 30 or polymeric having polymeric repeat in excess of 30 up to 300;

10 Tag is any known or novel tagging substrate;

 m are each independently selected from a whole number integer from 1 to 3;

15 p is 0 to 3

 characterised in that linking is at same or different linking sites in compounds comprising different Lig, J_L, L J_T and/or – Tag and is at different linking sites in compounds comprising same Lig, J_L, L J_T and/or – Tag.

20 Preferably the library does not comprise as Lig NECA, as Tag dansylamide or NBD, as each J a single bond and as L a methylene chain of C₃₋₁₂.

25 The innovation of the present invention relates to the design of specifically tagged ligands or “drugs” eg fluorescent ligands or “drugs” with known or selectable pharmacological properties. A key to this success is that each tag or fluorophore has a specific influence on the pharmacology of the resulting product, and it is incorrect to assume that the compound will retain the properties of the precursor drug. Preferably the library is constructed by the rational design of library members representing modifications in linking sites and ligand moieties, which can be used as 30 a basis for selection of a tagged or fluorescent ligand retaining the properties of the precursor ligand. Preferably the library comprises a plurality of defined and well

characterized tagged ligands, having verified properties corresponding to those of the non-tagged ligand.

A GPCR ligand may be selected from any compound which is effective as an agonist
5 or antagonist for an adenosine receptor, a beta-adrenoceptor, a muscarinic receptor, a histamine receptor, an opiate receptor, a cannabinoid receptor, a chemokine receptor, an alpha-adrenoceptor, a GABA receptor, a prostanoid receptor, a 5-HT (serotonin) receptor, an excitatory aminoacid receptor (e.g. glutamate), a dopamine receptor, a protease-activating receptor, a neurokinin receptor, an angiotensin receptor, an
10 oxytocin receptor, a leukotriene receptor, a nucleotide receptor (purines and pyrimidines), a calcium-sensing receptor, a thyroid-stimulating hormone receptor, a neurotensin receptor, a vasopressin receptor, an olfactory receptor, a nucleobase receptor (e.g. adenosine), a lysophosphatidic acid receptor, a sphingolipid receptor, a tyramine receptor (trace amines), a free-fatty acid receptor and a cyclic nucleotide
15 receptor or the like, preferably for a GPCR receptor for example a) an adenosine receptor antagonist b) an adenosine receptor agonist c) a beta-adrenoceptor agonist and d) a beta-adrenoceptor antagonist. Preferably a ligand is a non-peptide ligand.

An inhibitor of intracellular enzymes is preferably e) an inhibitor of an intracellular
20 enzyme such as an inhibitor of cyclic nucleotide phosphodiesterases; or a derivative or analogue thereof.

A substrate of a drug transporter is any drug that is transported into or out of the cell via the transporter. An inhibitor of a drug transporter is any compound which binds
25 to the transporter and prevents a substrate being transported. Thus, a tagged inhibitor can be used to bind to the transporter and localise it. A tagged substrate of the invention could be used to follow transport into or out of the cell and to test whether inhibitor drugs can prevent the transport of the tagged substrate. A substrate or inhibitor is preferably selected from a substrate or inhibitor of any equilibrium based
30 drug transporters or ATP driven pumps such as a catecholamine transporter, a nucleoside transporter, an ATP-binding cassette transporter, a cyclic nucleotide transporter or the like.

Preferably the library provides tagged ligands which are suited for surface cell receptor binding or for intracellular binding, or for penetrating or exiting live cells. Accordingly the library represents the rational design of compounds which are 5 predicted to have retained pharmacology and properties suitable for specific binding applications.

Each Tag may be independently selected from any entity which is known in the art of tagging molecules to form a marker or reporter group for detecting molecules and 10 which may be used in analytical studies relating to the ligand, particularly for visualisation, and includes but is not limited to fluorophore tags as known in the art. An additional Tag may be present and may perform a function *in situ*, eg may be any laser activated Tag which is activated to have a local or targetted therapeutic or destructive effect. This allows in a first stage visualising the compound of formula I 15 by means of a visualisation Tag, in a second stage activation of laser activated Tag, and optionally in a third stage visualising the compound of formula I or fragments thereof. For example a laser activated Tag may comprise malachite green which may be activated for targetted protein destruction.

20 In a particular advantage, in the case that Tag is a chemical entity which might be anticipated to inhibit receptor ligand binding or to inhibit intracellular enzyme or drug transporter inhibition in or by a compound of formula I such inhibition is negated or dispelled by the presence of group L and/or of each J or by the chosen site of linking in one or more library members.

25 Preferably one or more of each -Tag in one or more or each library compound is an entity -Fl and comprises any known or novel fluorophore, whereby the library comprises compounds of which one or more or all of which are of formula I'
$$(\text{LigJ}_L)_m \text{ L (J}_T \text{ Fl})_m (\text{J}_T \text{ L (J}_L \text{ Lig})_m)_p$$

30 Preferably each compound of formula I or I' comprises one of a plurality of fluorophores and/or tags providing a library of differently fluorescently tagged ligands comprising one or a number of different fluorophores (preferably of different

chemical composition, spectral characteristics etc); and/or providing a library of differently tagged ligands including at least one fluorescently tagged ligand; alternatively each compound of formula I or I' comprises one of a plurality of precursor ligands linked each to one or a plurality of different tags providing a library of same or differently tagged ligands of plural ligand type; alternatively each compound of formula I comprises one of a plurality of linkers linking a precursor ligand and at least one Tag at the same or different linking site; alternatively each compound of formula I comprises the same linker linking a precursor ligand and at least one Tag at different linking sites providing a library of differently linked tagged ligands of different conformation or anticipated pharmacology and binding.

In each case the library of the invention provides for the selection of a tagged ligand of desired binding affinity inhibition or transport at a desired receptor, intracellular enzyme or at or by a drug transporter with desired pharmacology, visualisation, mechanism or the like.

More preferably a library comprises a plurality of compounds of one or more of formula II to III’:

20 II $(\text{LigJ}_L)_m L J_T \text{Tag}_T L (J_L \text{Lig})_m$ where each m is as hereinbefore defined and is preferably 1 or 2, more preferably 1

III $(\text{LigJ}_L)_m L (J_T \text{Tag})_m$ where m in each is as hereinbefore defined and is preferably 1 and/or 2, more preferably

$\text{Lig J}_L - L - J_L \text{Tag}$ and/or

25 $\text{Lig J}_L - L - J_T \text{Tag}$ and/or $\text{Lig J}_L - L - J_T \text{Tag}$
 $\searrow J_L \text{Lig}$ $\searrow J_T \text{Tag}$

wherein each J_L and J_T comprises J as hereinbefore defined and may be same or different and may derive from functionality originally present in Lig or L and Tag or 30 L or a combination thereof, characterised in that linking is at same or different linking sites in compounds comprising different Lig, J_L , L , J_T and/or Tag, and is at

different linking sites in the case of any two or more compounds comprising identical Lig, J_L, L, J_T and/or Tag.

In one preferred embodiment the invention comprises a library of compounds of 5 formula I as hereinbefore defined wherein Lig, J_L, L, J_T and Tag are the same in all compounds, and wherein the compounds differ by site of linking thereof.

In a further preferred embodiment the invention comprises a library of compounds of 10 formula I or I' as hereinbefore defined wherein Lig and J_L are the same in all compounds and L and J_T are the same or similar in all compounds and Tag is different in some or all compounds.

In a further preferred embodiment the invention comprises a library of compounds of 15 formula I or I' as hereinbefore defined wherein Lig- and -Tag are the same in all compounds and -L- is different in all compounds.

The library may comprise from 3 to 250 tagged ligands. Preferably the library comprises from 1 to 10 families comprising 3 to 25 tagged ligands each family comprising a ligand moiety of a common ligand type and from 3 to 25 different tag 20 moiety types at least one of which is a fluorescent tag, more preferably each of which is a different fluorescent tag; or the library comprises from 5 to 250 fluorescently tagged ligands of different ligand type and different fluorophore type.

A library providing fluorescent ligands comprising different Fl is useful to enable 25 studying binding, inhibition or transport with different colour fluorescence for example to distinguish from same colour native fluorescence or to distinguish plural types of binding site, enzyme, transporter or the like.

It is known that ligands modified ie by linking to a fluorophore typically undergo a 30 change in binding affinity, inhibition or transport and suitably the library of the invention comprises characterisation of the pharmacology of each compound including binding affinity or inhibition or transport for certain GPCRs, intracellular

enzymes or drug transporters. Preferably the library includes information for each tagged ligand comprised in the library, relating to the pharmacology for binding to or inhibition of a GPCR receptor or to inhibition of an intracellular enzyme such as cyclic nucleotide phosphodiesterases, or inhibition of or transport by a drug 5 transporter including designation as agonist, antagonist, substrate or inhibitor and measure of affinity or inhibition etc, enabling quantification of results.

In the prior art methods of preparing ligands the linking sites have in many cases been non-specific or unknown, as in the case of Molecular Probes ligands, or at best 10 have been specific or known but not predetermined, designed or rationalised for a desired effect. Preferably in the library of the invention tagged ligands comprise fluorophores linked at any of a number of linking sites at which ligand receptor binding, inhibition or transport is maintained to a greater extent or is modified or inhibited to a lesser extent. Preferably the library comprises tagged ligands designed 15 from reaction of reactive precursor ligand(s) and reactive fluorophores having reactive site chemical functionality and suited for reaction with associated reagents, for site specific reaction and linking, wherein the design is the result of extensive investigation of all or many of the possible linking sites and the resulting pharmacological characteristics and selection of one or more linking combinations 20 which provide favorable binding, inhibition or transport characteristics.

Preferably Lig is selected from

- a) xanthine like structures including XAC, theophylline, caffeine, theobromine, dyphilline, enprofylline and the like; or fused biaryl structures including papaverine, 25 dihydroquinilones such as cilostamide, dipyridamole, vincocetine and the like; and analogues thereof;
- b) adenosine like structures including ADAC, NECA and analogues thereof;
- c) ethanolamine like structures including Salmeterol, salbutamol, terbutaline, quinprenaline, labetalol, sotalol, bambuterol, fenoterol, reprotohol, tulobuterol, 30 clenbuterol and analogues thereof;
- d) oxypropanolamine like structures including CGP12177, propranolol, practolol, acebutalol, betaxolol, ICI 118551, alprenolol, celiprolol (celectol),

metoprolol (betaloc), CGP20712A, atenolol, bisoprolol, misaprolol, carvedilol, bucindolol, esmolol, nadolol, nebivolol, oxprenolol, xamoterol, pindolol, timolol and analogues thereof;

e) xanthine like structures including XAC, theophylline, caffeine, theobromine,
5 dyphilline, enprofylline, sildenafil, EHNA (erythro-9-(2-hydroxyl-3-nonyl)adenine),
zaprinast and the like; or spiro bicyclic structures including bypyridines such as
amrinone, imidazolines such as CI930, dihydropyridazinones such as indolan,
rolipram, SB207499, and the like; or fused biaryl structures including papaverine,
10 dihydroquinilones such as cilostamide, dipyridamole, vincocetine and the like and
analogues thereof.

Linker L may perform a number of functions including preventing loss of affinity of
a ligand when modified to comprise a fluorescent moiety, by distancing the
fluorophore moiety from the ligand structure, in cases that modifying by direct
15 linking of Lig and Fl would interfere with ligand binding, inhibition or transport in
which case a linker L may be designed as a short, medium or long chain structure as
appropriate.

A library compound of formula I or I' may optionally comprise functionality J as
20 hereinbefore defined derived from its synthesis by the reaction of one or more
reactive group(s) of a linker precursor or its components, providing a linker moiety,
with a reactive group of one or more ligand precursors providing a ligand moiety and
reaction of one or more other reactive group(s) of the linker precursor with a reactive
group of one or more tag precursors such as a fluorescent tag precursor providing a
25 tag moiety.

In a particular advantage of the present invention linker L and/or linking site or
functionality J facilitates linking of fluorescent moiety and ligand, in cases that
groups of respective moieties are not reactive, or that stereochemistry or other effects
30 would inhibit linking, or that reaction of existing reactive groups in commercially
available precursor ligands and fluorophores would require the inclusion of
protecting groups for functionalities present therein, in which case a linker is usually

derived from a short, medium or long chain structure. In a further advantage linker – L- may be derived from a tri-, tetra-, penta- or hexa-functional precursor, linking 3 or more ligands Lig and tags Fl, enabling modified or more complex binding, inhibition or transport and associated pharmacology, for example binding to a plurality of 5 receptor sites to explore receptor dimerisation such as homo or heterodimerisation. In a further advantage of the invention linker L may confer properties facilitating crossing the cell membrane, hydrophobicity, hydrophilicity and the like as required, in which case a linker is usually any functionalised structure.

10 Preferably L is selected from a saturated or unsaturated single or double bond, -O-, -S-, amine, COO-, amide, -NN- hydrazine; and saturated or unsaturated, substituted or unsubstituted C₁₋₆₀₀, preferably C₁₋₃₀₀, more preferably C₁₋₁₀₀ branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, wherein optional 15 substituents are selected from any C₁₋₂₀ aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, carbonyl and the like.

20 More preferably L is selected from a single bond, -O-, -S-, amino; and branched or straight chain C₁₋₅₀ alkyl, alkenyl, alkynyl, alkoxy, amino, cycloalkyl, heterocyclic, aryl, heteroaryl, and combinations thereof such as aralkyl, aralkylamino, aralkylamido and the like, optionally comprising one or more heteroatoms wherein 25 heteroatoms are as hereinbefore defined, optionally substituted as hereinbefore defined wherein substituents are selected from C₁₋₁₂ aliphatic, aromatic or alicyclic substituents as defined, hydroxy, thiol, halo, amine, oxo, carbonyl, and the like.

30 J_L and J_T may comprise functionality derived from a reactive group or site for linking to fluorophore and/or to ligand selected from a saturated or unsaturated single or double bond, -O-, -S-, amino, amido, hydrazine, carbonyl, oxo, alkyl, alkenyl, alkynyl, alkoxy, thioxy, and the like.

In the case that L comprises a single or double bond, J_L and J_T if present may comprise functionality derived from a reactive group or site for linking linker and fluorophore derived from the fluorescent moiety and/or the ligand moiety.

5 Preferably the moiety J_{Lm} L J_{Tm} comprises a mono, di, tri, tetra, penta or hexa amino, alkylthio, alkoxy, carboxylic acid, and combinations thereof more preferably a mono, di or tri aminoalkylthio, amino alkoxy, alkoxy carboxylic acid, alkoxy amine and the like. Preferably J_{Lm} L J_{Tm} is selected from mono, di or tri amino methane, amino ethane, thio ethane, ethane, amino acyl, from polypeptide, or from mono or polyether derivatives thereof eg diamine or dithio such as mono or polyethylene glycol di or tri amine or thio.

10

15 Preferably a linker moiety J_{Lm} L J_{Tm} as hereinbefore defined comprises a single or double bond or a single atom or group as hereinbefore defined or comprises a mono-, di-, tri- or tetrafunctional linear or branched or cyclic substituted or unsubstituted hydrocarbyl of formula $-L-I-$

$J[A]q_L R_L [A'q_{L'} J']_{m-1} A''q_{L''} J''$

20 wherein each of J to J'' is a linking site or functionality as hereinbefore defined independently selected from a single bond, methylene, alkyne, alkene, NR, O, NRCO, S, CO, NCO, CHHal, P and the like wherein R is H or C_{1-8} alkyl or cycloalkyl or forms part of a cyclic ring with N, Hal is any halogen selected from chlorine, iodine, bromine; and is present in any rational location in a group A to A'' ;

25 each of A to A'' is a group selected from $-O-$, $-C(=O)-$, C_{1-12} alkoxy, alkoyl, cycloalkyl, heterocyclic, alkyl, alkenyl, aryl, arylamide, arylamine, amino, thioalkyl, heteroaryl as hereinbefore defined and combinations thereof and the like, optionally substituted by groups selected independently from C_{1-3} alkyl, C_{1-5} alkoxy and the like;

30 each of q_L to $q_{L''}$ are independently-selected from 0 or 1 or indicates an oligomeric repeat and is from 2 to 30, or indicates a polymeric repeat unit and is from 31 up to 300.

R_L is a C, N or S atom or is a CR_L , NR_L , alkyl, cycloalkyl, heterocyclic, aryl heteroaryl, amine or thio moiety and provides for branching when p is 1 or 2; wherein R_L is H or C_{1-3} alkyl; and
 p is as hereinbefore defined and is 0, 1 or 2.

5

Preferably each J , J' and J'' independently is a single or double bond, NR_L , $-O$ or $-S$ or $-C(O)$ or $-NRC(O)$ or $-C(O)NR$; as hereinbefore defined

A is alkoxy preferably CH_2CH_2O (PEG) and oligomers thereof or is aralkylamine aralkylamide, aralkyloxy, or is alkyl, preferably $(CH_2)_{1-10}$

10

12

R_L is a C_{1-5} alkyl chain comprising or containing a single or double branching C atom when p is 1 or 2;

p is 0, 1 or 2;

A' and A'' are each selected from C_{1-8} alkyl, amine, phenylamine, phenylamide; and

15

q_L is 0, 1, 2 to 30 or 31 to 300, and $q_{L'}$ and $q_{L''}$ are 0 or 1

More preferably J_{Lm} L J_{Tm} is a single bond or is of formula

$J A q_L R_L J''$

20 wherein each of J and J'' is amine or $-O-$, A is CH_2CH_2O , q_L is 1-30 or 31 to 300 and R_L is CH_2CH_2

or of formula

$J A q_L R_L (A' J') J''$

wherein each of J , J' and J'' independently is amine, $-O$ or a single bond, q_L is 1, 2 or

25 3 -30 or 31 to 300 and A is CH_2CH_2O or $HNCH_2CO$ or q_L is 1 and A is $C(O)$ or $(CH_2)_{1-8}$ or q_L is 0, R_L is CH or CH_2CH , $q_{L'}$ is 0 or $q_{L''}$ is 1 and A' is CH_2 and $q_{L''}$ is 0 preferably

$O(CH_2CH_2O)q_L CH_2CH_2NH$, $O(CH_2CH_2O)q_L CH_2CH(CH_2NH)NH$,

$OCH(CH_2NH)NH$, $-CH(CH_2NH)NH$, $-C(O) NH$, $-(CH_2)_{1-8}-$, $(-HNCH_2CO-)_{1-3}$ (= -

30 gly_{1-3-}) - or the like.

More preferably each compound of formula I or I' as hereinbefore defined comprises a moiety Lig and L as hereinbelow defined:

Wherein:

Lig.a_m is suitably of the formula, in either of the following forms given, including
 5 any of its possible linking configurations or sites:

Lig.a¹_m




Wherein
 10 any or each of Ra¹ to Ra⁴, X¹ and X² may comprise a linking site or functionality J as hereinbefore defined
 X¹ and X² are each independently selected from H, O, OR.a, NR.a, NHR.a;
 X¹ and X² are each preferably O;
 each of R.a, R.a¹, R.a² and R.a³ independently is selected from H or
 15 C₁₋₄ linear or branched alkyl, preferably H, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl or isobutyl optionally mono or multi hydroxy or halo substituted, such as CH₂OH, CH₂F or CH₂CHOHCH₂OH;
 R.a⁴ is selected from a heteroatom O, S or substituted or unsubstituted
 20 amine or saturated or unsaturated, substituted or unsubstituted C₁₋₂₀ branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C₁₋₁₂ aliphatic, aromatic or alicyclic substituents
 25 any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like;

preferably R.a⁴ is selected from optionally substituted aryl, cycloalkyl, alkyl, ketone, (di)amine, (di)amide, more preferably optionally substituted alkoxy, cycloalkyl, amine, amide, carboxylic acid or optionally o-, m- or p- substituted phenyl wherein substituents include aryl, alkyl, cycloalkyl, heteroaryl or heteroalkyl, amine, amide, carboxyl, carbonyl etc, for example substituents include, or R.a⁴ comprises, cyclohexyl, cyclopentyl, ethoxy, (CH₂)₂PhPh, CH₂Ph, CONH(CH₂)_nCONH, CH₂CONH(CH₂)₂NH, CH₂PhNHCOCH₂, CH₂CH₂OCOCH₂, succinimidyl ester, NHCOCH₂, CH₂(CH₃)NCOCH₂, H₂N(CH₂)₂NHCOCH₂, H₂N(CH₂)₈NHCOCH₂, H₂NNHCOCH₂, CH₂CONH(CH₂)₂NHCOCH₂, HOPhCH₂N(CH₂CH₃.HOAc)(CH₂)₂NHCOCH₂, heterocyclic-(CH₂)₄CONH(CH₂)₂NHCOCH₂, heterocyclic-NHCON(heterocyclic)COCH₂ and the like;

15

or Lig.a is of the formula Lig.a²-

20 Lig.a² 

wherein any or each of Ra⁵ to Ra⁶, or a cyclic C or heteroatom may comprise a linking site or functionality J as hereinbefore defined

each of C.A₁ and C.A₂ is independently selected from C₅₋₆ aryl, heteroaryl, cycloalkyl and heterocyclic, more preferably from phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring -C=C- group;

25 Each of up to seven R.a⁵ is a substituent of a ring carbon or a ring heteroatom and:

30 is independently selected from H, halo, hydroxy, thiol, amine, COOH, hydrazine, cyano, saturated or unsaturated, substituted or unsubstituted C₁₋₂₀ branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are selected from any C₁₋₁₂

aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, such as =O, OCH₃, CH₂Ph(OCH₃)₂, O(CH₂)₃CON(CH₃)₂, N(CH₂CH₂OH)₂, c.hex, COOCH₂CH₃, CH₂CH₃;

5 or any two or more of R.a⁵ form a one, two or three ring fused cyclic structure, preferably comprising a fused 3 ring aryl, 5-heterocyclic, 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig.a² structure;


and R.a⁶ is a moiety as defined for R.a⁵ above;

10 and L.a is as hereinbefore defined for L or J_L L J_T and is suitably of formula L.I or subformulae as hereinbefore defined, more preferably is selected from a single bond, amino acid or amide such as a peptide or polypeptide for example gly or gly₃, alkyl of formula -(CH₂)_n where n is 3 to 8, preferably 3, 4 or 6, optionally including one or more heteroatoms or unsaturated groups, such as -O- or -S- or -CH=CH- and the like;

15

Lig.b is suitably of the formula Lig.b including any of its possible linking configurations or sites:

20 Lig.b



wherein any or each of Rb¹ to Rb⁵ or Xb¹ to Xb³ may comprise a linking site or functionality J as hereinbefore defined

25 ring substituents X.b¹ and X.b² are independently selected from hydrocarbon such as alkyl or SR_X, NR_{X.2} and OR_X wherein (each) R_X is selected from H, C₁₋₅alkyl, alkenyl;

ring heteroatom X.b³ is selected from -S-, -O- and -CH₂-;

5 Rb¹ is selected from saturated or unsaturated, substituted or unsubstituted C₁₋₄ aliphatic, or C₁₋₃ alicyclic optionally including one or more heteroatoms N, O, S, P, wherein substituent(s) are selected from one or more cycloalkyl, heterocyclic, hydroxy, oxo, halo, amine; preferably R.b¹ comprises a carbonyl substituted by H, alkyl or a linear or cyclic primary, secondary or tertiary amine, substituted C₁₋₃ alkyl, cycloalkyl or amide, more preferably cyclopropyl, or CONHC₁₋₃alkyl such as CONHET or CH₂OH

10 and each of R.b² and R.b³ is selected from H, halo, hydroxy, thiol, amine, COOH, CHO, hydrazine, cyano or saturated or unsaturated, substituted or unsubstituted C₁₋₂₀ branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C₁₋₁₂ aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, preferably from H, halo or hydroxy, preferably H or Cl;


15 Rb⁴ is H;

20 Rb⁵ is H or alkyl

25 L.b may comprise a linking site or functionality J as hereinbefore defined; and is as hereinbefore defined for L or its subformulae, more preferably is saturated and unsaturated substituted or unsubstituted C₁₋₁₂ aliphatic or C₁₋₂₄ aromatic as defined for L preferably including one or more heteroatoms O, S or N, cyclic or heterocyclic groups, more preferably is of formula L.I or its subformulae as hereinbefore defined, most preferably is (CH₂)_m wherein m is 2 to 12, preferably 3, 4, 6 or 8, or is (Ph-CH₂CONH)₂ (CH₂)₂;

30 Lig.c is suitably a non-peptide of the formula Lig.c including any of its possible linking configurations or sites:

Lig.c $\text{HOCH}_2\text{NH-R.c}^2$




Where any or each of Rc^1 to Rc^2 or OH, or a chain C or N may comprise a
5 linking site or functionality J as hereinbefore defined

* indicates an optically active centre and

Wherein R.c^1 is C_{6-14} aryl optionally including one or more heteroatoms selected
from H, O, optionally substituted by OH, Hal eg Cl, NH_2 , NHC_1 ,
alkyl, sulphonamide, oxoamine (-CONH₂) and the like, more
10 preferably mono, di or tri substituted phenyl or quinoline wherein
substituents include OH, Cl or NH_2 , more preferably m-CH₂OH, p-
OH phenyl, m-,p-dihydroxy phenol or m-,m-dihydroxyphenol, m-,m-
diCl, p-NH₂ phenol, p-OH, m-CONH₂ phenol or 5-OH, 8-quinoline
and the like, such as

15




20

R.c^2 is selected from saturated or unsaturated, substituted or
unsubstituted C_{1-20} , preferably C_{1-12} , branched or straight chain
aliphatic, aromatic, alicyclic and combinations thereof, any of which
may comprise one or more heteroatoms selected from N, O, S, P;
wherein optional substituents are selected from any optionally
substituted C_{1-12} aliphatic, aromatic or alicyclic substituents any of
which may comprise one or more heteroatoms as hereinbefore
defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the
like and combinations thereof;

25

Preferably R.c^2 is selected from C_{1-6} branched or straight chain aliphatic, C_{6-10}
araliphatic optionally substituted by OH and optionally including
heteroatoms selected from N,O, preferably including an ether O, such

as selected from $-(CH_2)_6OCH((CH_2)_3Ph)$, $CHCH_3(CH_2)_2Ph$, $CHCH_3CH_2PhOH$, $C(CH_3)_2CH_2$ or from the structures:




5

L.c may be present as R.c² or may comprise a linking site or functionality J as hereinbefore defined, and is as hereinbefore defined for L and is suitably of formula L.I or its subformulae as hereinbefore defined, 10 more preferably is selected from C₁₋₁₂ alkyl, amide etc;

Lig.d is suitably a non-peptide of the formula Lig.d including any of its possible linking configurations or sites:

15 Lig.d R.d¹ OCH₂C*HOHCH₂NH-R.d²




where any or each of R.d¹ to R.d² or OH, a chain C or N may comprise a linking site or functionality J as hereinbefore defined

* indicates an optically active centre

20 Wherein R.d¹ is saturated or unsaturated, substituted or unsubstituted C₁₋₂₀ branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C₁₋₁₂ aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like;


Preferably R.d¹ is substituted or unsubstituted C₁₋₂₄ aralkyl or heteroaralkyl, including single ring and fused ring systems with (hetero)aryl or cycloalkyl rings, wherein optional substituents include C₁₋₆ alkyl, alkoxy, ether, carbonyl, alkenyl, amine, amide each optionally carbonyl, amide, halo or OH substituted, or halo such as chloro or OH, preferably R.d¹ is unsubstituted or substituted alkyl, alkenyl, halo, amine, amide, carbonyl, ketone, ether substituted phenyl or naphthyl, illustrated as follows, most preferably mono-, di-, tri- or tetra substituted mono or polycyclic fused aryl or cycloaryl or heterocycloaryl such as phenyl, carbazole or structures shown below or spiro ring systems, most preferably mono-, di-, tri- or tetra alkoxyalkyl, alkoxyalkoxyalkyl or CF₃ substituted phenyl or unsubstituted or monosubstituted naphthalene or 5,6 ring systems most preferably of the structures:



R.d² is substituted or unsubstituted amine, saturated or unsaturated, substituted or unsubstituted C₁₋₁₂ branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P; wherein optional substituents are selected from any C₁₋₁₂ aliphatic, aromatic or alicyclic substituents any of which may comprise one or more

5

heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, more preferably amine, C₁₋₆ branched or straight chain alkyl optionally including ether O, and optionally substituted by C₆₋₁₀ aryl, for example i.pr, i.bu, or of the formula:



L.d may be present as R.c² or may comprise a linking site or functionality J as hereinbefore defined and is as hereinbefore defined for L and its subformulae and is suitably of formula L.I and its subformulae as hereinbefore defined, more preferably is a single bond or is as hereinbefore defined for L.a;

Lig.e comprises a cell permeant moiety or is associated with a cell permeant L or Fl moiety and is suitably of the formula , in either of the following forms given 15 including any of its possible linking configurations or sites:


20 Lig.e¹



wherein any or each of Re¹ to Re⁴, X and a ring C or N may comprise a linking site or functionality J as hereinbefore defined


h is selected from

5



10

each optionally substituted by R.e³ – R.e⁴ wherein R.e¹ – R.e⁴ are as R.a¹ – R.a⁴ defined above or in which R.e³ is C₅₋₉ linear or branched alkyl, optionally mono or multi hydroxy or halo substituted or is aryl optionally substituted by alkoxy, sulfonyl and the like

eg ortho-OEt, meta-SO₂N₊  NCH₃

15

each X is independently selected from H, O, -OR.e², N, HN, NR.e⁵, HR.e⁶, and aryl optionally substituted by ether; or X is aryl optionally alkyl or alkoxy substituted such as Ph-ortho-OCH₂CH₂CH₃;

20


and where R.e⁵ is as defined above for R.e¹ above or forms a fused cyclic ring together with the adjacent ring N atom; preferably 1 or 2 fused 5 membered cyclic rings;

25

and R.e⁶ is as defined above for R.e¹ above or is selected from optionally substituted phenyl wherein optional substituents include ether such as o-ethoxy or o-propoxy, alkyl, OH and the like, sulphonyl, carbonyl and the like substituted by heterocyclic, or cyclic C₅₋₈ alkyl such as methyl, piperazinyl, sulphonyl and the like;

5 or Lig.e is of the formula Lig.e²

Lig.e²




Wherein any or each free ring atom or their substituents may comprise a
 10 linking site or functionality J as hereinbefore defined
 each spiro ring optionally comprises zero or one or more heteroatoms h which are
 preferably N, more preferably (h) comprises zero or 1 N
 heteroatom and 5,6(h) comprises
 15 zero, 1 or 2 N heteroatoms and is unsaturated or comprises one or two
 -C=C- or -C=N- groups;
 and wherein each ring is optionally substituted by one or more oxo,
 CO, COOH, C₁₋₆ alkyl or linear or cyclic alkoxy such as methoxy,
 ethoxy or cyclopentyloxy optionally substituted by one or more oxo,
 20 CO, COOH, CN, or C₁₋₆ alicyclic or amine groups, amine or one or
 more spiro or fused heterocycles;

or Lig.e is of the formula Lig.e³

25

Lig.e³



30

Wherein any or each of Re¹¹ to Re¹², or a ring C or heteroatom or ring
 substituent may comprise a linking site or functionality J as
 hereinbefore defined

each of C._{E1} and C._{E2} is independently selected from C₅₋₆ aryl, heteroaryl, cycloalkyl and heterocyclic, more preferably from phenyl, or aryl containing 1 or 2 ring heteroatoms, or heterocyclic containing 1 ring heteroatom and/or 1 ring -C=C- group;

5 Each of up to seven R.e¹¹ is a substituent of a ring carbon or a ring heteroatom and:
is independently selected from saturated or unsaturated, substituted or unsubstituted C₁₋₂₀ branched or straight chain aliphatic, aromatic, alicyclic and combinations thereof, any of which may comprise one or more heteroatoms selected from N, O, S, P, and wherein optional substituents are
10 selected from any C₁₋₁₂ aliphatic, aromatic or alicyclic substituents any of which may comprise one or more heteroatoms as hereinbefore defined, hydroxy, thiol, halo, amine, hydrazine, oxo, cyano, and the like, such as =O, OCH₃, CH₂Ph(OCH₃)₂, O(CH₂)₃CON(CH₃)c.hex, N(CH₂CH₂OH)₂, c.hex, COOCH₂CH₃, CH₂CH₃;
15 or any two or more of R.e¹¹ form a one, two or three ring fused cyclic structure, preferably comprising a fused 3 ring aryl, 5-heterocyclic, 6-heterocyclic structure having 4 ring atoms common with the fused bicyclic Lig.e³ structure;
and R.e¹² is a moiety as defined for R.e¹¹ above;

20 Preferably Lig.e is of the formula Lig.e¹ as hereinbefore defined in particular where R.e² and R.e³ are respectively propyl and butyl;

25 L.e may comprise a linking site or functionality J as hereinbefore defined and is suitably as hereinbefore defined for L.a.

Linking sites J as hereinbefore defined are suitably of any nature and location, ie any sites, which do not inhibit binding, inhibition or transport. Receptor binding is complex, and may require a specific binding site to be available and/or require a
30 specific fluorescent ligand conformation.

The fluorescent ligands of the library of the invention may be characterised by different linking sites linking ligand and fluorescent moiety as hereinbefore defined. From a comprehensive knowledge of the binding, inhibition or transport behaviour and the specific target sites, which remain unchanged in the fluorescent ligands of 5 the invention, we have been able to determine a method for selecting suitable linking sites for desired retention of binding, inhibition or transport and pharmacological properties. Preferably the compounds of formula I or I' include compounds representing all operative linking configurations exposing possible binding, inhibition or transport site options.

10

F1 may include any red, green, near ir, blue or the like absorbing dyes and other classes of dyes. Suitably F1 is selected from dyes in particular including fluorescein, fluorescein derivatives including FITC, and fluorescein-like molecules such as Oregon Green™ and its derivatives, Texas red™, 7-nitrobenz-2-oxa-1,3-diazole 15 (NBD) and derivatives thereof, coumarin and derivatives, naphthalene including derivatives of dansyl chloride or its analogues or derivatives, Cascade Blue™, EvoBlue and fluorescent derivatives thereof, pyrenes and pyridyloxazole derivatives, the cyanine dyes, the dyomics (DY dyes and ATTO dyes) and fluorescent derivatives thereof, the Alexafluor dyes and derivatives, BDI dyes including the commercially 20 available Bodipy™ dyes, erythrosin, eosin, pyrenes, anthracenes, acridines, fluorescent phycobiliproteins and their conjugates and fluoresceinated microbeads, Rhodamine and fluorescent derivatives thereof including Rhodamine Green™ including the tetramethylrhodamines, X-rhodamines and Texas Red derivatives, and 25 Rhodol Green™, coupled to amine groups using the isocyanate, succinimidyl ester or dichlorotriazinyl-reactive groups and other red, blue or green absorbing fluorescent dyes in particular red absorbing dyes as reviewed in Buschmann V et al, Bioconjugate Chemistry (2002), ASAP article.

More preferably F1 is selected from fluorescein derivatives and fluorescein-like 30 molecules such as Oregon Green™ and its derivatives, Texas red™, 7-nitrobenz-2-oxa-1,3-diazole (NBD) and derivatives thereof, coumarin and derivatives, naphthalene including derivatives of dansyl chloride or its analogues or derivatives,

Cascade Blue™, EvoBlue and fluorescent derivatives thereof, pyrenes and pyridyloxazole derivatives, the cyanine dyes, the dionics (DY dyes and ATTO dyes) and fluorescent derivatives thereof, the Alexafluor dyes and derivatives, BDI dyes including the commercially available Bodipy™ dyes, erythrosin, eosin, FITC, 5 pyrenes, anthracenes, acridines, fluorescent phycobiliproteins and their conjugates and fluoresceinated microbeads, Rhodamine derivatives thereof including Rhodamine Green™ including the tetramethylrhodamines, X-rhodamines and Texas Red derivatives, and Rhodol Green™.

10 More preferably F1 comprises fluorescein, Texas Red™, Cy5.5 or Cy5 or analogues thereof, BODIPY™ 630/650 and analogues thereof, DY-630, DY-640, DY-650 or DY-655 or analogues thereof, ATTO 655 or ATTO 680 or analogues thereof, EvoBlue 30 or analogues thereof, Alexa 647 or analogues thereof.

15 Suitably F1 is derived from any of the above commercially available fluorophores, comprising or modified to comprise a reactive group facilitating linking to a ligand by a moiety J as hereinbefore defined. Preferably F1 comprises any of the above commercially available fluorophores modified to form a derivative or group of derivatives suitable for visualising ligand binding, inhibition or transport in a library 20 as hereinbefore defined comprising $J_T - t - F1$ wherein J_T is as hereinbefore defined and comprises functionality derived from linking to a precursor ligand as hereinbefore defined and may optionally comprise a linking group $-t-$ which is a proximal unsaturated or aryl moiety, comprising a medial short, medium or long chain alkynyl or cycloalkyl moiety and comprising a moiety derived from linking via 25 a reactive group as hereinbefore defined such as carboxyl, sulphonate or as a heteroatom such as O or S or methylene derived from linking at an alkylhalide such as methylbromide, haloacetamide, sulphonate ester or the like electrophilic group.

For example F1 may include a substituent $-t-$ which performs a fluorescence 30 modifying function, for example is a heteroaryl or alkenyl such as mono-, di- or tri- enyl group which shifts the fluorescence of the compound to the red part of the spectrum and raises the absorption max value, or performs a linking function.


Preferred BODIPY™ (4,4-difluoro-4-bora-3a,4a-diaz-s-indacene) fluorophores include those which span the visible spectrum and include those listed in U.S. Pat. No. 4,774,339; U.S. Pat. No. 5,187,288; U.S. Pat. No. 5,248,782; U.S. Pat. No. 5,274,113; U.S. Pat. No. 5,433,896; U.S. Pat. No. 5,451,663. A preferred member of this group is selected from any heteroaryl substituted BODIPY™ dyes as described in the above patents the contents of which are incorporated herein by reference.

10 Suitably $J_T - t - F1$ comprising a BODIPY™ structure is characterised by a dipyrrometheneboron difluoride core, optionally modified by one or two fused rings, optionally substituted by one or several substituents such as alkyl, alkoxy, aryl, heterocyclic and the like, wherein one substituent $-t-$ is adapted for linking as hereinbefore defined to a ligand precursor as hereinbefore defined, the substituent $-t-$ 15 optionally comprising a proximal unsaturated or aryl moiety, comprising a medial short, medium or long chain alkynyl or cycloalkyl moiety and comprising a moiety derived from linking via a reactive group as hereinbefore defined such as carboxyl, sulphonate or as a heteroatom such as O or S or methylene derived from linking at an alkylhalide such as methylbromide, haloacetamide, sulphonate ester or the like electrophilic group.

20 $F1$ may include a substituent $-t-$ as hereinbefore defined which is heteroaryl or alkenyl such as mono-, di- or tri-enyl group which shifts the fluorescence of the compound to the red part of the spectrum and raises the absorption max value as in US 5187288; or may include alkenyl substituent linked to one or more of an aryl, 25 carbonyl or like group, preferably linked to a fatty acid sidechain comprising $(CH_2)_nCO_2H$ where $n = 5 - 22$ as in US 5330854, more preferably linked via an aryloxymethylene to a and carbonyl; or may include an aryl alkenyl aryl group as in US 6005113.

30 More preferably $-F1$ is of the formula $-F1^1$:

Fl¹ dipyrrrometheneborondifluoride analogues including any of its possible linking configurations or sites:




Wherein any or each of R¹ to R⁷, or a ring atom may comprise a linking site or
5 functionality J as hereinbefore defined

R7 is N or C-R8;

Substituents R¹, R², R³, R⁴, R⁵, R⁶ and R⁸ which may be the same or different
are H, halogen, nitro, sulfo, cyano, alkyl, perfluoroalkyl, alkoxy, alkenyl, alkynyl,
10 cycloalkyl, arylalkyl, or acyl wherein the alkyl portions of each contain fewer than
20 carbons; or substituted or unsubstituted aryl or heteroaryl; preferably at least four
of R¹ to R⁸ are non-hydrogen, alternatively adjacent substituents R1 and R2 taken in
combination and adjacent substituents R5 and R6 taken in combination form fused 6-
membered (hetero) aromatic rings

or



15

including any of its possible linking configurations or sites:

wherein any or each of R³, R⁴ or R⁷, or a ring atom may comprise a linking site
or functionality J as hereinbefore defined

each fused ring is optionally and independently substituted by H, halogen, nitro,
20 sulfo, cyano, alkyl, perfluoroalkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, alkylthio,
alkylamido, amino, (mono or dialkyl)amino (wherein the alkyl portions of each
contain fewer than 20 carbons), or substituted or unsubstituted aryl, heteroaryl,
arylamido, heteroarylamido, aryloxy, heteroaryloxy, arylamino or heteroarylamino;
or 1 to 2 additional fused benzo or heteroaromatic rings that are optionally
25 substituted or unsubstituted.

Preferably any or all of R^{2,3} to R^{4,5} is heteroaryl, more preferably a single ring single heteroatom such as such as pyrrole, thiophene, furan or single ring di heteroatom structure such as oxazole, isoxazole, oxadiazole, imidazole, or multi ring such as benzoxazole, benzothiazole, benzimidazole, or multi ring one heteroatom structure 5 such as benzofuran, indole, preferably thienyl.


More preferably F1 is selected from the BODIPY core structures of formulae FL.A1 or FL.A2 as shown below, in each case = indicating the attachment site of a sidechain and including any of its possible linking configurations or sites:



10


FL.A1

preferably comprising or derived from BODIPY TMR or BODIPY FL (4,4-difluoro-5,7dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic acid) or BODIPY FL 15 ethylene diamine including any of its possible linking configurations or sites:




BODIPY TMR

BODIPY FL ethylene diamine (X is CONH(CH₂)₂NH₂) or BODIPY FL (X is COOH)




20

Or FL.A2 including any of its possible linking configurations or sites:




preferably comprising or derived from BODIPY 630/650 or BODIPY 630/650 methyl bromide including any of its possible linking configurations or sites:


5 BODIPY 630/650 methyl bromide



BODIPY 630/650



BODIPY 630/650 X



10

most preferably the succinimidyl esters thereof, for example BODIPY 630/650 X-SE.

In a further aspect of the invention there is provided a process for the preparation of a library as hereinbefore defined comprising the reaction of one or each of a plurality of ligand precursors and tag precursors comprising linker moieties or ligand, tag and linker precursors wherein linking may be at same or different reactive sites in 5 different compounds as hereinbefore defined.

Preferably the process is a combinatorial process. Preferably the process comprises the reaction of one or more ligand precursors of formula IV and/or IV'

IV $(\text{LigJ}_L)_m - L - Y_{Lm}$

10 IV' $\text{Lig } Y_{\text{Lig}}$

comprising one or more or different reactive groups Y_L or Y_{Lig} forming a linking functionality J , J_L or J_T as hereinbefore defined

with one or more of a plurality of analytical tagging substrates of formula V and/or V'

15 V $Y_{Tm} \text{ Tag}$

V' $Y_{Tm} L (J_T \text{ Tag})_m$

comprising one or more or different reactive groups Y_T forming a linking functionality J or J_T as hereinbefore defined

and optionally one or more linking species VI or VI' or VI''

20 VI $Y_{Lm} L Y_{Lm}$

wherein Lig, J , L , J_T and Tag and each m is independently as hereinbefore defined

wherein the or each compound of formula IV or IV' is capable of reaction with the or each compound of formula V or V', optionally via the or each species VI or VI' or VI'' to form a plurality of compounds of formula I as hereinbefore defined.

25

Preferably in some or each compound of formula V or V', Tag is Fl as hereinbefore defined, whereby the process is a process for preparing a library comprising a plurality of compounds of which one or more or all of which are of formula I' as hereinbefore defined.

30


Suitably reactive groups Y_{Lig} , Y_L , Y_T have suitable reactive group functionalities for linking, as hereinbefore defined, for example by substitution or by addition or

addition – elimination reaction. Substitution reaction is suitably selected from reaction of electrophilic and nucleophilic reactive sites as hereinbefore defined such as:

	Electrophilic	Nucleophilic	Resulting covalent	leaving
5	Y	Y	Linkage, J	groups
	Carboxylic acid	alcohol	ester	-OH, -H
	Carboxylic acid	amine	carboxamide	-OH, -H
	Carboxylic acid	hydrazine	hydrazide	-OH, -H
10	Alkyl halide	alcohol	ether	-Hal, -H
	Alkyl halide	thiol	thioether	-Hal, -H
	Alkyl halide	amine	alkylamine	-Hal, -H
	Alkyl halide	COOH	ester	-Hal, -H
	Haloacetamides	thiols	thioethers	-Hal, -H
15	Sulphonate esters	amines	alkyl amines	RSO ₃ -, -H
	Sulphonate esters	alcohols	ethers	RSO ₃ -, -H
	Sulphonate esters	thiols	thioethers	RSO ₃ -, -H
	Sulphonyl halides	amines	sulphonamides-Hal,	-H
	Sulphonyl halides	alcohols	sulphonate esters	-Hal, -H
20	Succinimide ester	alcohols	esters	-OSu*, -H
	Succinimide ester	alkoxides	esters	-OSu*, H or M ⁺
	Succinimide ester	thiols	thioesters	-OSu*, -H
	Succinimide ester	amine	carboxamide	-OSu*, -H
	Succinimide ester	hydrazine	hydrazide	-OSu*, -H

25

wherein * is



Addition reaction is suitably selected from cycloaddition or addition-elimination reaction of electrophilic and nucleophilic reactive sites in IV and V as hereinbefore defined:

	Electrophile	Nucleophile	Covalent	Leaving
5	Y	Y	Linkage, J	Group
	azide	alkyne	triazole*	none
	2-acyl cyclic mono- /di-ketone	dinucleophile eg hydrazine	6,7-dihydro-1H-indazol-4(5H)-one 4,5,6,7-tetrahydro-1H-indazole	H ₂ O H ₂ O
	(5 or 6 mem ring)		1,4,5,6-tetrahydrocyclopenta[c]pyrazole	H ₂ O
10			5,6-dihydrocyclopenta[c]pyrazol-4(1H)-one	H ₂ O

wherein * is [3+2] dipolar cycloaddition

Preferably a compound of formula IV or IV' comprises no protecting group and is capable of reaction with a compound of V or V' optionally via a compound of VI, without degradation of functionality by choice of reaction and of respective reactive sites; or a compound of formula IV or IV' comprises one or more protecting groups which are adapted for removal under ambient conditions, for example under neutral pH, room temperature or the like. Preferably the process comprises reaction wherein reactive groups Y are selected so as to enable reaction with a fully deprotected ligand ie without the need for protecting groups or so as to enable reaction with protecting groups present which may be removed under mild conditions, for example one of Y_{Lig} or Y_L or Y_T comprises amine or alcohol or thiol and the other comprises succinimide ester.

In the case that choice of reactive groups requires protection of compounds of formula IV or IV', a protecting group is preferably such as to allow removal under mild conditions, preferably comprises benzyloxycarbonyl and the like which are removed at ambient conditions such as room temperature or under conditions which do not prejudice functional groups such as the glycosidic group in Lig.b.

The process of the invention is characterised by a high yield of compounds of

formula I or I' as hereinbefore defined by use of chemoselectivity and is superior to known methods which prejudice yields by use of non chemoselective reactive groups or protecting groups.

5 Preferably the compounds of formula I or I' are obtained by:
reacting the unprotected primary alkyl amine group a compound of formula IV as hereinbefore defined with a compound of formula V comprising a reactive succinimidyl ester group in solvent at ambient temperature without need for subsequent deprotection. In a particular advantage of the invention the method
10 provides greater yield than with the prior art processes.

Compounds of formula IV, IV', V', V' or VI may be commercially available or may be prepared by known means. A linker may be installed as an independent entity or may be constructed as part of a synthetic process as hereinbefore defined, preferably
15 is synthesised as an additional substituent on the ligand moiety or fluorescent moiety prior to reaction thereof.

In a further aspect of the invention there is provided a process for the preparation of a compound of formula I as hereinbefore defined comprising the reaction of a
20 compound of formula IV or IV' and a compound of formula V or V' and optionally additionally VI, as hereinbefore defined.

In a further aspect of the invention there is provided a process for the preparation of a compound of formula IV as hereinbefore defined comprising: obtaining where
25 commercially available or preparing the ligand precursor Lig, by routes as known in the art, and reacting with linker precursor VI'', if required, or components thereof, and/or generating one or more reactive sites Y or Y_{Lig} or Y_L . Protection of IV may be required in which case reaction is followed by removing any protecting group present during the reaction, optionally replacing with a protecting group which may
30 be removed under ambient conditions. A reactive group Y or Y_{Lig} or Y_L is preferably selected from groups as hereinbefore defined.

Preferably the process comprises:

- a), e) ring closure of 5,6-diamino-1,3-dialkyl uracil with the appropriate substituted aldehyde under acid conditions with ferric chloride,
- b) reacting Lig.b- comprising a protected inosine derivative with chlorinating agent and linking the chloro derivative with the amine group of a suitably protected amine reactive linker H-L-P_L wherein P_L comprises *N*-benzyloxycarbonyl- to form Lig.b - L-P_L and removing P_L to generate Lig.b -L.b; preferably R.b¹ comprises a OH terminating group and protected inosine comprises Acyl protecting groups or R.b¹ comprises a stable group such as amine or amide and protected inosine comprises 2,2-dimethoxypropane protecting group; preferably the protected inosine is reacted with oxidising agent and protected alkylamine which is an *N*-alkylcarboxamide with removal of amine protecting group to generate a reactive ligand;
- c), d) reacting *p*-hydroxybenzaldehyde with formaldehyde under acid catalysis and protection of the resulting 4-hydroxy-3-hydroxymethylbenzaldehyde with dimethoxypropane to generate the resulting acetonide. Converting the Benzaldehyde to its corresponding epoxide and ring opening with a suitably protected linker such as Boc-L.c-H supplies Lig_m-L-P_L. Finally, deprotection under acid conditions supplies Lig.cLc or Lig.dLd for coupling to an appropriate tag.

20 In a particular advantage of the present invention linker moiety L facilitates linking of fluorescent moiety and ligand moiety, in cases that moieties are not reactive, or that stereochemistry or other effects inhibit linking, or that reaction of existing reactive groups in commercially available compounds of formula IV or IV' and V or V' would require the inclusion of protecting groups for functionalities present

25 therein, in which case a linker is usually a difunctional short, medium or long chain structure. In a further advantage of the invention linker L may confer properties facilitating crossing the cell membrane, hydrophobicity, hydrophilicity and the like as required, in which case a linker is usually any functionalised structure.

30 Preferably a linker precursor of formula VI as hereinbefore defined is selected from a heteroatomic species such as a species providing N, O, S, or P, or a branched or straight chain saturated or unsaturated, optionally heteroatom containing, C₁₋₆₀₀

reactive hydrocarbon and combinations thereof, which may be monomeric, oligomeric having oligomeric repeat of 2 to 30 or polymeric having polymeric repeat in excess of 30 up to 300 and comprises reactive groups or sites for linking to ligand and fluorophore selected from hydroxy, alkoxy, thiol, thioxy, amine, hydrazine, 5 carbonyl and the like. In the case that a linker comprises a single bond, then a reactive site is usually present on the compound of formula IV', whereby is reactive with compound of formula V or V'.

10 Preferably a compound of formula VI comprises three, four, five or six reactive sites, for linking 3 or more ligands and tags of formula IV or V. Preferably a linker precursor is selected from any substrate which generates or donates a moiety L as hereinbefore defined.

15 Suitably a linker precursor of formula VI is a short, medium or long chain, comprising rationally designed functionality and comprising reactive sites providing functionality in moiety L as hereinbefore defined. Preferably a linker precursor of formula VI is a mono, di or mixed amine, hydroxy, thiol, carboxylic acid, acid chloride, acid fluoride, acid bromide, (acid halide), isocyanate NCO, isothiocyanate NCS, halide, alkylhalide, aldehyde, epoxide, sulphonyl chloride SO_2Cl or hydrazine 20 NHNH_2 , more preferably is selected from mono, di or tri amino methane, amino ethane, ethanethiol, hydroxy ethane, amino acid, from polypeptide, or from mono or polyether derivatives thereof eg diamine or dithiol such as mono or polyethylene glycol di or tri amine or thiol.

25 Preferably a linker precursor of formula VI is selected from any C_{1-12} substituted or unsubstituted alkylamine, aminoacid, cycloalkyl, aryl, heteroaryl, aralkyl, and the like providing one or more reactive end groups for linking to Fl, more preferably selected from (di)amine, comprising cyclic or linear amine, more preferably diamine methane, or diamino ethylene, amino acid or polypeptide, or from mono or 30 polyether diamine such as polyethylene glycoldiamine, more preferably from $\text{H}_2\text{N}(\text{CH}_2)_4\text{NHCO}_2\text{CH}_2\text{Ph}$, $\text{H}_2\text{N}(\text{CH}_2)_5\text{NHCO}_2\text{CH}_2\text{Ph}$, $\text{H}_2\text{N}((\text{CH}_2)_2\text{O})_2(\text{CH}_2)_2\text{NHCO}_2\text{CH}_2\text{Ph}$ and $\text{H}_2\text{N}(\text{CH}_2)_n\text{NHBOC}$ where n is 2 to 8.

Preferably a linker precursor comprises a linear or branched or cyclic substituted or unsubstituted alkyl having one, two or three reactive sites, of formula $Y_{Lm} L_I Y_{Lm}$ wherein L_I is as hereinbefore defined

5

Preferably each Y_L is independently selected from H, CO_2H , NH_2 , O, P, S and groups providing on reaction a single bond, alkyl such as methylene, alkyne, alkene, NH , NR , O, $NRCO$, S, CO, NCO, $CHHal$, P and the like wherein Hal is any halogen selected from chlorine, iodine, bromine, or

10 wherein Y_L comprises protecting leaving groups Z_L such as $-NHCO_2CH_2Ph$, H, OH, SH, halogen, amine, aliphatic, N-alkylcarboxamide, Boc and the like;

In a further aspect of the invention there is provided a method for selecting a compound of formula I from a library as hereinbefore defined comprising the 15 rational design of a library of compounds of formula I as hereinbefore defined using the process as hereinbefore defined, determining pharmacology for a plurality of or all compounds in the library and selecting a compound exhibiting desired pharmacology at a desired target.

20 Preferably the method comprises preparing a preliminary library of compounds, conducting screens to assess binding, inhibition, transport and the like, selecting compound identified in the screen as having beneficial properties, and modifying or functionalising by nature of moieties or linking location of linking on the basis of the indications from the screen to prepare an optimised library. In a particular advantage 25 of the invention the molecular pharmacology and photochemistry from the screen feedback into the design of the library.

The linker strategy is in some cases specific for the tag to be used, whereby 30 modifying the tag may require modifying the linker. We have surprisingly found that modifying a moiety without consequential modification of other moieties may result in an inactive compound which is for example incapable of binding.

In a further aspect of the invention there is provided a known or novel compound of formula I or I' as hereinbefore defined wherein the compound is associated with information relating to its pharmacological properties in the form of Spectral Properties given as Excitation Max and Emission Max, Fluorescence Lifetime and 5 Emission quantum yield and Pharmacology defined in terms of cells expressing a GPCR receptor as hereinbefore defined or expressing an intracellular enzyme such as a cyclic nucleotide phosphodiesterase, or a drug transporter as hereinbefore defined and given as the Inhibition or Antagonism of receptor binding or of receptor functionality together with a value for the Inhibition (pK_B) or Antagonism (pK_I) 10 binding constants, and optionally together with fluorescent images of the pharmacological binding in single living cells illustrating the defined inhibition or antagonism.

15 Preferably the compound is associated with information relating to its pharmacological properties wherein pharmacology is defined in terms of a cell or protein wherein the cell expresses a GPCR, intracellular enzyme or drug transporter or the protein is a GPCR, intracellular enzyme or drug transporter preferably in terms of a CHO cell comprising GPCR receptors as hereinbefore defined, preferably selected from an adenosine receptor such as an A_1 -, A_{2A} -, A_{2B} - and A_3 -receptor, a 20 beta-adrenoreceptor such as an β_1 , β_2 - and β_3 - adrenoceptors or like receptor, or comprises an inhibitor of an intracellular enzyme such as cyclic nucleotide phosphodiesterases or a substrate or inhibitor of a drug transporter as hereinbefore defined; more preferably in terms of CHO-cells expressing human adenosine A_1 -receptor or beta-adrenoceptor or an inhibitor of an intracellular enzyme such as an 25 inhibitor of intracellular phosphodiesterases. The pharmacological properties are given as EC_{50} values for agonist stimulated – or pK_I values for antagonism of agonist stimulated second messenger generation, or substrate K_m values or antagonist K_i values for stimulation or inhibition of intracellular enzymes or drug transporters.

30 Preferably a novel compound is of the formula I or I' as hereinbefore defined, more preferably is selected from formulae $Lig.a_m L.a-Fl.a_n$ to $Lig.e_m L.eFl.e_n$ as hereinbefore defined

with the proviso that:

- a) when Lig is XAC ie in Lig.a when each of R.a¹ and R.a² is propyl, R.a³ is H and R.a⁴ is -Ph-OCH₂CONH(CH₂)₂NH-, and L is a single bond or L is gly and n=3 or L is NCS, Fl is not fluorescein; or
- 5 when Lig is XAC and L is a single bond or NCS, Fl is not fluorescein or NBD;
- b) when Lig is adenosine Fl is not Fmoc (CA 134:204756); or
 - when Lig is ADAC , ie R.b¹ is CH₂OH, R.b² and R.b³ are H and L is -(Ph-CH₂CONH)₂(CH₂)₂- or L is a single bond, Fl is not fluorescein, NBD or Rhodamine; or
- 10 when Lig is NECA (incorporating the moiety -(CH₂)_m) ie R.b² and R.b³ are H and L is a single bond, or is -(CH₂)_m when m is 2,4,6,8 or 10 then Fl is not NBD, or when m is 3,4,6,8,10 or 12 then Fl is not dansyl; or
 - when Lig is *N*⁶-[2-(4-aminophenyl)ethyl]adenosine and L is (CH₂)₂PhNH, Fl is not FITC (CA 131:56155 (8))
- 15 d) when Lig is CGP12177 and L (R.d²) is mono amine menthane, Fl is not BODIPY® TMR; or
 - when Lig is CGP12177 and L is 1,1,4,4-tetramethyl butylamine, i.e C(CH₃)₂(CH₂)₂C(CH₃)₂NH- Fl is not BODIPY® FL, or when L is C(CH₃)₂(CH₂)₂C(CH₃)₂NHCSNH- then Fl is not FITC, eosin or erythrosin; or when
- 20 L is monoamine menthane, Fl is not FITC (CA 131:56155 (4)); or
 - when Lig is CGP12177 and L is a single bond, Fl is not NBD; or
 - when Lig is alprenolol i.e o-prop-2-enyl phenyl and L is -C(CH₃)₂- or a single bond, Fl is not NBD.
- 25 Optionally additionally
 - a) when Lig is XAC ie in Lig.a when each of R.a¹ and R.a² is propyl, R.a³ is H and R.a⁴ is -Ph-OCH₂CONH(CH₂)₂NH-, and L is a single bond Fl is not BODIPY™ 630/650; or
 - b) when Lig is ABEA, ie m is 4 and L is a single bond Fl is not BODIPY™ 630/650.
- 30

Preferably a ligand or fluorescent ligand of the invention is an agonist which maintains its binding affinity and its functional activity or is an antagonist which maintains its binding affinity on linking or when linked to fluorescent moiety Fl. Fluorescent ligands may have affinity such that they bind permanently, semi-permanently or transiently, ie may retain bound or may be washed away when unbound ligand is washed away.

Fluorescent ligands of the invention may be inherently optically active or may be functionalised, in known manner, to be optically active, and any such ligand may be present as a racemate or as one of its optically active isomers.

In a further aspect of the invention there is provided a novel reactive ligand of formula IV or IV' as hereinbefore defined or library thereof useful for linking to any suitable tag of formula V or V' as hereinbefore defined,

15 with the proviso that

when Lig is Lig.a and is 1,3-dialkyl xanthine as hereinbefore defined wherein X¹ and X² are =O, R.a³ is H, R.a¹ and R.a² are both CH₃ or both n-C₃H₇, then R.a⁴ is not 4-hydroxyphenol or PhOCH₂CO₂H; or

when R.a¹ and R.a² are both n-C₃H₇, then R.a⁴ is not PhOCH₂OCNHPH₂OH;

20 PhOCH₂OCONsuccin, PhOCH₂CONH₂, PhOCH₂CONH(CH₂)₂NH₂,
PhOCH₂CONH(CH₂)₈NH₂, PhOCH₂COHNNH₂, or
PhOCH₂CONH(CH₂)₂N(CH₂CH₃.HOAc)CH₂PhOH; or

when Lig is CGP12177 then L is not -(CH₃)₂(CH₂)₂C(CH₃)₂NH₂ (CA 121:103486; or

25 when Lig is aden, L is not -(CH₂)₂S(CH₂)₂NH₂ (CA 125:218348; or L is not (CH₂)₆NH₂ or CH₂CONH(CH₂)₆NH₂ (CA 134:2043); or L is not (CH₂)₂NH₂ or (CH₂)₂O(CH₂)₂O(CH₂)₂NH₂ (CA 135:25706); or L is not (CH₂)_nNH₂ where n is 2 – 12 (CA 108:715);

or when Lig is alprenolol L is not (CH₂)₈NH₂ or when Lig is propranolol L is not (CH₂)₄NH₂ (CA 124:8848)

30 or when Lig is alprenolol L is not CH₂C(CH₃)₂NH₂ (CA 108:215827)

or when Lig is ICI 118551 L is not $(CH_2)_2NH_2$ or when Lig is propranolol L is not $(CH_2)_2NH_2$ (CA 98:4564)

5 Preferably a novel ligand-linker comprising a compound of formula IV wherein components are as hereinbefore defined and a reactive group Y_{Lig} is as hereinbefore defined, preferably of formula Lig L.I or Lig.LI' as hereinbefore defined.

In a further aspect of the invention there is provided a novel fluorophore linker of formula V or V' as hereinbefore defined or library thereof.

10

In a further aspect of the invention there is provided a kit comprising ligand precursors, linker precursors and tag precursors of formulae IV, IV', V, V' and/or VI as hereinbefore defined for preparing a library of compounds of formula I as hereinbefore defined.

15

In a further aspect of the invention there is provided the use of a fluorescent ligand of formula I or I' as hereinbefore defined or library thereof for visualising receptors or receptor binding, assessing pharmacological properties of the fluorescent ligand, in high throughput screening of novel chemical entities that bind to the target receptor, 20 in inhibiting an intracellular enzyme or inhibiting a drug transporter or a substrate of a drug transporter, in studying drug transport or drugs suitable for transport, in distinguishing healthy or diseased tissue and the like. Preferably the use comprises using any fluorescence detection technique more preferably confocal microscopy or fluorescence correlation spectroscopy. Preferably the use allows to calculate ligand 25 affinity constants and concentration of sub-populations of a receptor type, intracellular enzyme or drug transporter as hereinbefore defined.

In a further aspect of the invention there is provided a method for receptor binding or inhibition, intracellular enzyme inhibition or drug transport or inhibition and 30 visualisation comprising contacting a fluorescent ligand as hereinbefore defined with a sample in manner to facilitate binding or inhibition thereof or transport thereby, and detecting changes in fluorescence or location thereof.

A sample may comprise cell material, selected from cells, cell extracts, cell homogenates, purified or reconstituted proteins, recombinant proteins or synthesised proteins and the like, and includes a target for the compound of formula I. Samples 5 comprising cell material may be derived from plants, animals, fungi, protists, bacteria, archae or cell lines derived from such organisms. Animal or plant cells used to prepare the sample may be healthy or dysfunctional and are optionally used in the diagnosis of a disease such as leukaemia or cancer. In a preferred embodiment of the invention the sample comprises mammalian cells, extracts and homogenates thereof.

10

Preferably a sample comprises live cell material, more preferably including individual cells or sub cell compartments, most preferably comprising GPCRs, intracellular enzymes or drug transporters in living cells, membrane containing these proteins, solubilised receptors, enzymes or drug transporters or GPCR arrays. Cell 15 material may be obtained in known manner by culturing cells or by expressing proteins in cells.

In a preferred embodiment the cell material is a cell expressing a GPCR, enzyme or drug transporter. GPCR's are possibly the single most important class of targets for 20 current and prospective drug therapies.

More preferably the sample comprises GPCR receptors selected from adenosine A₁-, A_{2A}-, A_{2B}- and A₃-receptors, β₁, β₂- and β₃- adrenoceptors, or comprises inhibitors 25 of intracellular enzymes such as cyclic nucleotide phosphodiesterases, most preferably CHO-cells expressing human adenosine A₁-receptor or beta-adrenoceptor or an inhibitor of an intracellular enzyme such as an inhibitor of intracellular phosphodiesterases.

Cell material may be tagged prior to contact with the fluorescent ligand, for example 30 by tagging with GFP, for example GFP tagged GPCR's, GFP tagged intracellular enzymes and GFP tagged drug transporters, or a native receptor, intracellular enzyme or a drug transporter to which a fluorescent antibody has been targetted, to allow

visualising of the cell receptors, enzymes or transporters, and overlay with the fluorescent ligands.

Receptors may be provided in membrane samples or in acutely dispersed cell
5 samples, for example endogenous receptors such as A₁-AR in acutely dispersed cells. The adenosine receptor binding site is located deep within the pocket of the receptor, whereby a fluorescent ligand with linker is a preferred fluorescent (ant)agonist. Whilst there is considerable freedom in modifying the ligand and retaining antagonist binding activity, it is harder to retain agonist activating activity, ie activating the
10 receptors functions on binding.

The method for drug transport of a substrate of a drug transporter would be to follow the uptake of the compound of formula I into the cell cytosol (if the transporter moves the drug into cells) OR after loading the cells with substrate to follow the
15 disappearance of the compound of formula I from the cells and its appearance in the extracellular medium (if the transporter moves the drug out of the cells – for example in the case that the transporter is an ATP-driven pump). Preferably the method comprises monitoring transport of a drug into a cell via an equilibrium transporter that moves the compound into the cell - then applying an inhibitor of this first
20 equilibrium transporter, and monitoring the export of the drug from the cells via an ATP-driven pump transporter.

The method of inhibition of a drug transporter may be monitored by detecting binding to the transporter on the cell surface.

25 Preferably the method including detecting a change in fluorescence includes detecting a change in the intensity, excitation or emission wavelength distribution of fluorescence (single and multi photon), fluorescence lifetime, fluorescence polarisation or a combination thereof or the like. The optical response is detected by
30 known means such as cameras, film, laser-scanning devices, fluorometers, photodiodes, quantum counters, microplate, microscopes, fluorescent microscopes such as epifluorescence or confocal, cytometers, readers and the like, preferably

CSLM, confocal plate readers, fluorescence polarisation plate readers or FCS. Where the sample is examined using a flow cytometer, examination of the sample optionally includes sorting components of the sample according to their fluorescence response.

5 A method for binding or inhibition or detection according to the invention may be *in vitro* or *in vivo*.

In a particular advantage of the invention the novel fluorescent ligands are suitable for use in combination with FCS enabling the study of ligand-receptor binding at the 10 single molecule level. Because of the nature of the events being monitored FCS is ideal for the study of thermodynamic and kinetic features of molecular interactions in solution. Another particular advantage of the invention is that the FCS approach can be adapted to monitor ligand-receptor binding at the single molecule level using photon counting fluorescence intensity measurements. This removes any requirement 15 for the molecules to be moving within the confocal volume.

With ligands showing low background fluorescence it is not necessary to remove unbound ligand by washing before performing either confocal microscopy or FCS. It is therefore possible to measure fluorescence with time, in both time and 20 concentration dependent manner.

Confocal microscopy (CSLM) allows visualisation of a section through a cell showing concentration of fluorophore at the cell edges indicating membrane receptor binding. Visualisation is of a particular plane of focus such that a "slice" through an 25 individual cell may be observed, as known in the art. Different coloured channels may be selected to visualise different fluorophore types.

FCS is a non-invasive technique which analyses the diffusion characteristics of 30 fluorescent species through a very small excitation volume ($<10^{-15} \text{ l}$) by statistically analysing the pattern of their photon emissions. Thus fast-diffusing free ligand can be distinguished from slowly-diffusing receptor-bound ligand and quantified simultaneously when the volume is localised to the cell membrane. Preferably the

method incorporating FCS comprises measuring fluctuations in fluorescence intensity in a confocal volume of $<10^{-15}\text{l}$. Statistical analysis of these fluctuations gives information about the speed of diffusion (i.e. mass) and concentration of the fluorescent molecules present. Thus free ligand (fast diffusing) and bound ligand 5 (slow diffusing) can be quantified simultaneously on a single cell.

FCS (fluorescence correlation spectroscopy) correlates fluctuations in fluorescence emission of particles to parameters such as particle mass and concentration for the study of molecular interactions in solution. FCS essentially monitors spontaneous 10 fluorescence intensity fluctuations of fluorescently tagged molecules in a microscopic detection volume (10^{-15}l) through analysis by a tightly focused laser beam.

These fluctuations provide information on the rate of diffusion or diffusion time of a 15 particle which is directly dependent on the mass of the given molecule. When small and therefore rapidly diffusing molecules pass through the path of the laser they produce rapidly fluctuating fluorescence intensity patterns, whereas when larger molecules pass through the beam they produce bursts of fluorescence that are more sustained. Consequently the increase in the mass of a biomolecule, eg as a result of 20 ligand binding, is detected as an increase in the diffusion time of the resultant biomolecule.

Fluorescence microscopy may be used to localise receptors at single cell or sub 25 cellular level with sensitivity and speed. In this way high affinity tagged ligands could help to elucidate molecular characteristics of GPCR receptor subtypes, such as adenosine and the like receptors, their regional distribution and cellular localisation.

In a further aspect of the invention there is provided the use of a fluorescent target 30 for the fluorescent ligand, for example, a Green Fluorescent Protein-tagged receptor, intracellular enzyme or drug transporter. In this case the spectral characteristics of the fluorescent ligand are chosen to allow separate detection of the location of both the fluorescent ligand and the fluorescent receptor, intracellular enzyme or drug

transporter. Cross-correlation fluorescence correlation spectroscopy or fluorescence intensity measurements will then allow the quantitative analysis of ligand-receptor, ligand-enzyme, ligand-drug transporter or drug transport interactions in a single measurement. This is distinct from prior art methods involving GFP-protein 5 translocation assays and assays involving fluorescence energy transfer (FRET). Figure 1 exemplifies this approach.

In a further aspect of the invention there is provided a cell surface GPCR modified on its N-terminus or a naturally occurring domain to express a short epitope tag for a 10 commercially available antibody (e.g. myc, haemagglutinin, FLAG). This is then expressed in CHO cells and a fluorescent antibody to the tag sequence is used in living cells to provide two-colour analysis of fluorescent ligand-receptor interactions as described for GFP-tagged proteins above.

15 In a further aspect of the invention there is provided CHO cells expressing a cell surface GPCR modified as claimed in Claim 37 for use with a fluorescent antibody to the tag sequence is used in living cells to provide two-colour analysis of fluorescent ligand-receptor interactions as described for GFP-tagged proteins above.

20 In a further aspect of the invention there is provided a kit comprising a compound of formula I or I' as hereinbefore defined and a target therefore provided as a cell line, membrane derived from such a cell line or protein solubilised from that cell line. The cell derived material may be provided in one of three forms: (1) from cells expressing a green fluorescent protein tagged receptor, intracellular enzyme or drug 25 transporter; (2) from cells expressing an epitope tag for a commercially available fluorescent antibody or (3) a wild-type protein for which a specific fluorescent antibody is also provided.

30 In an alternative embodiment there is provided a kit comprising a compound of formula I or I' as hereinbefore defined and a fluorescent antibody to a native protein which can be used in native (non-recombinant) cells.

In each case, the spectral characteristics of the compound of formula I or I' and fluorescent antibody or green fluorescent protein are selected to allow optimum two-colour cross-correlation fluorescence correlation spectroscopy (single or multiphoton).

5

The invention is now illustrated in non-limiting manner with reference to the following figures and examples and accompanying synthesis schemes:

In the Figures:

10 Figure 1 shows images taken from confocal microscopy imaging of a) fluorescence derived from XAC BY-630 binding to receptors on the surface of CHO cells observed at the red channel, b) fluorescence derived from green fluorescent protein fused to the C terminus of the human adenosine A₁-receptor, expressed by CHO cells indicating receptor locations observed via the green channel and c) overlaid images from a) and b) showing overlap of fluorescence and therefore confirming ligand binding is specific to receptors.

15

In the Schemes:

Scheme 1 shows synthesis routes for the synthesis of an adenosine receptor antagonist Lig - L - Fl_L

20

Schemes 2 and 3 show synthesis routes for the synthesis of two adenosine receptor agonists Lig - L - Fl_L including the synthesis of ligand precursor Lig - L - Z_L from linker precursor Z_L'-L-Z_L

Scheme 4 shows synthesis routes for the synthesis of two beta adrenoceptor agonists

25 Lig - L - Fl_L including the synthesis of ligand precursor Lig - L - Z_L from linker precursor Z_L'-L-Z_L

Examples A - C

30 The following compounds are synthesised or modelled and binding affinity studied:

Example A1 / B1 / C1 Adenosine receptors antagonists:

XAC – BODIPY 630/650 (1)

Example A2 / B2 Adenosine receptor agonists:

Adenosine-BODIPY 630/650 (2)

5 NECA-BODIPY 630/650 (3) (ABEA – BODIPY 630)

APEA-BODIPY 630/650 (3a)

ABIPEA - BODIPY 630/650 (3b)

Example A3 / B3 Beta-adrenoreceptor agonists

10 Salmeterol – BODIPY 630/650 (4)

Clenbuterol – BODIPY 630/650 (9)

Example A4 / B4 Beta-adrenoreceptor antagonists

CGP12177-BODIPY 630/650 (5)

15 Propranolol-BODIPY 630/650 (6)

ICI118551-BODIPY 630/650 (7)

Alprenolol – BODIPY 630/650(8)

Example A5 / B5 Inhibitors of cyclic nucleotide phosphodiesterases

20 XAC – BODIPY 630/650 (1)

Materials and Methods

The ¹H NMR spectra were acquired on a Bruker AM 250 (250 MHz) spectrometer, 25 in CDCl₃ or DMSO-*d*₆. Chemical shifts (δ) are recorded in ppm with reference to the residual solvent signal/TMS. Coupling constants (J) are recorded in hertz, and signal multiplicities are described by s (singlet), d (doublet), dd (doublet of doublets), t (triplet), m (multiplet), br (broad). Where given, assignments are made based on homonuclear correlation spectroscopy (COSY-45) and, where available, are in full 30 agreement with literature values (Jacobsen KA *et al.*, *J. Med. Chem.* (1985), **28**, 1341-6).

(Analytical RP-HPLC was performed on a Waters Millenium LC system with 996 PDA eluent detection, using a Vydac C⁸ column (150mm x 4.6 mm) at a flow rate of 1.0 mL·min⁻¹. The mobile phases used were: Solvent A, water, (degassed by helium bubble); Solvent B, acetonitrile, (degassed by sonication)).


5

A. SYNTHESIS

Example A1 –Synthesis of adenosine based fluorescent A₁-receptor antagonists

1. XAC-BY630 (1)

10




Scheme 1

Reagents and conditions: (i) BODIPY 630/650-X-SE, DMF 2 h, RT, (72%).

15 XAC-BODIPY 630/650 was synthesised by reacting the primary alkyl amine group of XAC with BODIPY®-630/650-X-succinimidyl ester (Molecular Probes). XAC and BY630 were stirred in N,N-dimethylformamide for 2h at room temperature and the product purified by HPLC. XAC and analogues were synthesised by the method of Jacobsen *et al* J. Med. Chem 1985, 28, 1334-1340.

20




TOF ES+ found 974.3998 (C₅₀H₅₅BF₂N₉O₇S requires 974.4006)

R, 12.5 min (35-100% v/v B, 30 min)

δ_H 0.87, 0.90 (6H, overlapping t, *J* 9.3, *N*¹-, *N*³-CH₂CH₂CH₃), 1.14-1.25 (2H, m, C²⁴H₂), 1.36-1.62 (6H, m, C²³H₂, C²⁵H₂, *N*^{1/3}-CH₂CH₂CH₃), 1.68-1.78 (2H, m, *N*^{1/3}-CH₂CH₂CH₃), 2.04 (2H, t, *J* 7.3, C²²H₂), 3.04-3.19 (6H, m, C¹⁸H₂, C¹⁹H₂, C²⁶H₂), 3.86 (2H, t, *J* 7.4, *N*^{1/3}-CH₂CH₂CH₃), 4.01 (2H, t, *J* 7.1, *N*^{1/3}-CH₂CH₂CH₃), 4.52, 4.53 (4H, 2x s, C¹⁵H₂, C²⁹H₂), 6.95 (1H, d, *J* 4.2), 7.05-7.10 (4H, m), 7.27-7.30 (3H, m), 7.35-7.40 (2H, m), 7.41 (1H, br s), 7.54-7.65 (3H, m), 7.70 (1H, s), 7.77 (1H, s), 7.80-7.92 (2H, s), 8.01-8.23 (4H, m) (2 x C¹¹H, 2 x C¹²H, 2 x C³²H, 2 x C³³H, C³⁵H, C³⁶H, C³⁸H, C³⁹H, C⁴¹H, C⁴³H, C⁴⁴H, C⁴⁷H, C⁴⁸H, C⁴⁹H, N⁹H, N¹⁷H, N²⁰H, N²⁷H)

Example A2 - synthesis of adenosine based fluorescent agonists at the human A₁-adenosine receptor (A₁-AR) receptor based on 5'-N-ethylcarboxamidoadenosine (NECA) with maintained functional activity

Compounds 2, 3, 3a and 3b were synthesised by reaction of suitably protected inosine derivatives, specifically with a chlorinating agent allowing introduction of a protected linker. Removal of protecting groups preceded conjugation of a fluorescent agent via the linking group.




Scheme 2

Reagents and conditions: (a) Ac₂O, pyridine, 40°C, 1 h, 97%. (b) POCl₃, N,N-dimethylaniline, reflux, 5 min, 85%. (c) (i) H₂N(CH₂)₄NHR, DIEA, EtOH, reflux, 18 h, (ii) sat. NH₃/MeOH, 0°C, 2 h. 66%. (d) H₂, Pd/C, MeOH:H₂O:AcOH (7:2:1), r.t., 2 h, 80% (e) BODIPY 630/650-SE, DMF, r.t., 3 h, 63%

1. Adenosine-C⁴- BODIPY 630/650 (ABA-BY630) (2)

ABA-BY630 was synthesised using the method and reagents and conditions described in Scheme 2 a-e in which R is COCH₂Ph.



15

ES+ found 885.4 (C₄₃H₄₈BF₂N₉O₇S requires 885.4)

R, 22.5 min (5-100% v/v B, 30 min)



2. NECA – C⁴ - BODIPY 630/650 (ABEA-BY630) (3).

20

*N*⁶-aminobutyl-5'-deoxy-5'-oxo-5'-ethylaminoadenosine (ABEA) was synthesised from commercially available reagents in 6 steps. The primary amine group of ABEA

was acylated with the fluorophore BODIPY®630/650-X-succinimidyl ester (BY-630, Molecular Probes) to afford BY630-ABEA, which was purified by RP-HPLC (Scheme 3).

5 The synthesis is shown in Scheme 3, with use of linker precursor of formula $\text{H}_2\text{N}(\text{CH}_2)_4 \text{HNCOOCH}_2\text{Ph}$:



10

Scheme 3

15 **Reagents and Conditions:** (a) 2,2-Dimethoxypropane, TsOH, acetone, r.t., 18 h. (b) TEMPO, BAIB, MeCN:H₂O (1:1), r.t., 4 h. (c) (i) SOCl₂, DMF, CHCl₃, reflux, 6 h. (ii) EtNH₂, CHCl₃, 5°C, 30 min. (d) H₂N(CH₂)₄NHZ, DIEA, EtOH, reflux, 18 h. (e) 0.1 M HCl (aq), 50°C, 4 h. (f) H₂, Pd/C, MeOH:H₂O:AcOH (9:0.9:0.1), r.t., 3 h. (g) BODIPY 630/650-X-SE, DMF, r.t., 4 h.

20

Synthesis of linker modified ligand, compound of formula IV

2',3'-Isopropylideneinosine 1: Inosine (5.36 g, 0.02 mol) and tosic acid monohydrate (3.80 g, 0.02 mol) were suspended in a mixture of 2,2-dimethoxypropane (50 cm³) and acetone (200 cm³) and stirred for 18 h. Sodium hydrogen carbonate (2.52 g, 0.02 mol) and water (40 cm³) were added and the suspension stirred for 15 min. The suspension was evaporated to constant volume and the crude product recrystallised from the residual water, yielding the acetonide 1 (3.71 g, 60%) as white needles; mp 266-268 °C (from H₂O) (lit., 266 °C); $[\alpha]^{22}_D$ - 67.1 (c 0.59 in MeOH) (lit., $[\alpha]^{20}_D$ -66.9 (c 0.8 in MeOH)); δ_H (250 MHz; DMSO-*d*₆) 1.31 (3 H, s, CH₃), 1.53 (3 H, s, CH₃), 3.53 (2 H, m, C^{5'}H₂), 4.22 (1 H, m, C^{4'}H), 4.93 (1 H, dd, *J* 6.1 and 2.5, C^{3'}H), 5.26 (1 H, dd, *J* 6.1 and 2.9, C^{2'}H), 6.10 (1 H, d, *J* 2.9, C^{1'}H), 8.10 (1 H, s, adenine CH), 8.31 (1 H, s, adenine CH); δ_C (69.2 MHz; DMSO-*d*₆) 25.2, 27.0 (2 x acetonide), 61.4 (C^{5'}), 81.3 (C^{4'}), 83.8 (C^{3'}), 86.6 (C^{2'}), 89.6 (C^{1'}), 113.1 (4°), 124.4 (4°), 138.7 (CH), 146.1 (CH), 147.8 (4°), 156.5 (4°); *m/z* (ES+) 309 (MH⁺), 137 (M-ribose).

2',3'-Isopropylidene-5'-oxoinosine 2: Acetonide 1 (3.08 g, 10 mmol), TEMPO (313 mg, 2 mmol) and iodosobenzene diacetate (7.09 g, 22 mmol) were dissolved in MeCN: H₂O (1:1, 50 cm³) and stirred, with the exclusion of light, for 4 h. The solvents were carefully evaporated from the resultant suspension and the reaction residue sequentially triturated with acetone and diethyl ether to yield the acid 2 (2.67 g, 83%) as a white powder; mp 224-229 °C (from diethyl ether) (lit., 274-276 °C); (found: C, 48.55; H, 4.3; N, 17.0. C₁₃H₁₄N₄O₆ requires C, 48.45; H, 4.4; N, 17.4%); δ_H (250 MHz; DMSO-*d*₆) 1.33 (3 H, s, CH₃), 1.51 (3 H, s, CH₃), 4.68 (1 H, d, *J* 1.6, C^{4'}H), 5.36-5.44 (2 H, m, C^{2'}H and C^{3'}H), 6.30 (1 H, s, C^{1'}H), 8.02 (1 H, s, adenine CH), 8.27 (1 H, s, adenine CH), 12.42 (1H, br s, NH; δ_C (69.2 MHz; DMSO-*d*₆) 25.1, 26.7 (2 x acetonide), 83.9, 85.8, 90.0 (4 x CH), 112.9 (4°), 124.4 (4°), 140.0 (CH), 145.8 (CH), 148.2 (4°), 156.8 (4°), 171.8 (C=O); *m/z* (ES+) 323 (MH⁺), 137 (M-ribose).

6-Chloro-6-deoxy-5'-ethylamino-2',3'-isopropylidene-5'-oxo-5'-deoxyinosine 3: (N.B. Rigorously dry reaction conditions and under an inert atmosphere) acid **2** (967 mg, 3 mmol), was suspended in CHCl_3 (15 cm^3) to which was added *N,N*-DMF (581 μL , 7.5 mmol) and SOCl_2 (1.09 cm^3 , 15 mmol). The suspension was placed in a hot oil-bath and maintained at reflux for 6 h. The resultant solution was evaporated and the yellow oil dissolved in THF (20 cm^3) at 5 °C. Ethylamine (2.0 M solution in THF, 3.75 cm^3 , 7.5 mmol) was added drop wise, stirred at 5 °C for 15 min and allowed to warm to room temperature. The solvent was evaporated, the residue dissolved in DCM (25 cm^3) and washed with water (2 x 20 cm^3) and saturated brine solution (2 x 20 cm^3). The organic fraction was dried and evaporated to leave a yellow oil that was purified by column chromatography on silica (5 % MeOH-DCM) to give the title compound **3** (525 mg, 48%) as a yellow syrup; $[\alpha]^{19}\text{D} -12.9$ (c 0.50 in CHCl_3); δ_{H} (250 MHz; CDCl_3 ; Me_4Si) 0.78 (3 H, t, *J* 7.3, CH_2CH_3), 1.41 (3 H, s, CH_3), 1.64 (3 H, s, CH_3), 2.90-3.11 (2 H, m, CH_2CH_3), 4.74 (1 H, d, *J* 1.9, C^4H), 5.46 (1 H, dd, *J* 6.2 and 2.3, C^2H), 5.54 (1 H, dd, *J* 6.2 and 1.9, C^3H), 6.24 (1 H, d, *J* 2.3, C^1H), 6.28 (1 H, br s, NH), 8.35 (1 H, s, adenine CH), 8.68 (1 H, s, adenine CH); δ_{C} (69.2 MHz; CDCl_3 ; Me_4Si) 14.2 (CH_2CH_3), 25.0, 26.9 (2 x acetonide), 33.9 (CH_2CH_3), 82.9, 83.4, 86.7, 92.0 (4 x CH), 114.6 (4°), 132.3 (4°), 144.8 (CH), 150.9 (4°), 151.9 (4°), 152.2 (CH), 168.1 (C=O); *m/z* (ES-) 366 ((M-H)⁻), 153 (M-ribose).

20

***N*⁶-(4-Benzylxycarbonylaminobutyl)-5'-ethylamino-2',3'-isopropylidene-5'-oxo-5'-deoxyadenosine 4:** Chloride **3** (337 mg, 0.92 mmol) was dissolved in EtOH (10 cm^3) to which was added *N*-benzylxycarbonylbutan-1,4-diamine (305 mg, 1.37 mmol) and DIEA (159 μL , 0.92 mmol). The solution was placed in a hot oil-bath and maintained at reflux for 18 h. The resultant solution was evaporated and the yellow oil purified by column chromatography on silica (2.5 % MeOH-DCM) to give the title compound **4** (445 mg, 88%) as a pale yellow gum; δ_{H} (250 MHz; CDCl_3 ; Me_4Si) 0.99 (3 H, t, *J* 7.1, CH_2CH_3), 1.43 (3 H, s, CH_3), 1.55-1.71 (7 H, m, CH_3 and 2 x CH_2), 3.20-3.35 (2 H, m, CH_2), 3.55-4.01 (4 H, m, CH_2CH_3 and CH_2), 4.81 (1 H, s, CH), 5.10 (3 H, m, benzyl CH_2 and CH), 5.51 (1 H, d, *J* 5.9, CH), 5.71 (1 H, d, *J* 5.9, CH), 6.10 (1 H, br s, NH), 6.16 (1 H, br s, NH), 7.30-7.36 (5 H, m, aromatics), 7.86

(1 H, s, adenine CH), 8.22 (1 H, s, adenine CH); δ_{C} (69.2 MHz; CDCl_3 ; Me_4Si) 13.7 (CH_2CH_3), 25.1, 26.6 (2 x acetonide), 26.8, 27.0, 40.0, 40.4 (4 x CH_2), 61.5 (CH_2CH_3), 66.6 (benzyl CH_2), 84.1, 84.7, 87.0, 91.6 (4 x CH), 113.7 (4°), 128.1 (C), 128.5 (CH), 136.7 (4°), 139.9 (CH), 152.8 (CH), 154.9 (4°), 156.5 (CH), 169.4 (C=O); m/z (ES+) 554 (MH $+$), 341 (M-ribose).

5: Adenosine derivative 4 (261 mg, 0.47 mmol) was dissolved in 1 M $\text{HCl}_{(\text{aq})}$: 1,4-dioxane (1:1, 4 cm 3), placed in a 50 °C oil-bath and stirred for 4 h. The resultant solution was adjusted to ~pH 8 (satd. $\text{NaHCO}_{3(\text{aq})}$), saturated with NaCl and extracted with EtOAc (3 x 5 cm 3). The combined organic fractions were dried and evaporated and the crude product purified by preparative layer chromatography (10 % MeOH-DCM) to give the title compound **5** (160 mg, 66%) as a colourless oil; δ_{H} (250 MHz; $\text{DMSO-}d_6$) 1.08 (3 H, t, J 7.2, CH_2CH_3), 1.45-1.62 (4 H, m, C^2H_2 and C^3H_2), 2.98-3.06 (2 H, m, C^1H_2), 3.17-3.26 (2 H, m, CH_2CH_3), 3.37-3.53 (2 H, m, C^4H_2), 4.12-4.16 (1 H, m, C^3H), 4.31 (1 H, d, J 1.1, C^4H), 4.58-4.65 (1 H, m, C^2H), 4.99 (2 H, s, benzyl CH_2), 5.56 (1 H, d, J 6.5, $\text{C}^2\text{-OH}$), 5.76 (1 H, d, J 4.2, C^3OH), 5.96 (1 H, d, J 7.6, C^1H), 7.25-7.34 (6 H, m, aromatics and NH), 8.01 (1 H, br s, carbamate NH), 8.27 (1 H, s, adenine CH), 8.39 (1 H, s, adenine CH), 8.94 (1 H, t, J 5.6, amide NH); δ_{C} (69.2 MHz; $\text{DMSO-}d_6$) 14.9 (CH_2CH_3), 26.6, 27.1, 33.4, 39.5, 40.3 (5 x CH_2), 65.3 (benzyl CH_2), 72.2, 73.3, 84.9, 88.0 (4 x CH), 120.2 (4°), 127.9 (CH), 128.5 (CH), 137.5 (CH), 140.6 (4°), 152.6 (CH), 154.9 (4°), 156.3 (4°), 169.3 (4°); m/z (ES+) 514 (MH $+$).


25 *N*⁶-(4-Aminobutyl)-5'-ethylamino-5'-oxo-5'-deoxyadenosine (ABEA) 6: Adenosine derivative **5** (48 mg, 0.09 mmol) was dissolved in MeOH:H₂O:AcOH (9:0.9:0.1, 5 cm 3), to which was added 10 % Pd/C (10 mg). The flask was evacuated, filled with hydrogen (balloon) and stirred vigorously for 3 h. The reaction mixture was filtered through celite and the celite washed with MeOH. The combined organic filtrates were evaporated and the resultant oil evaporated again from MeCN (2 x 15 cm 3) to give the title compound **6** (35 mg, quant.) as a colourless oil; δ_{H} (250 MHz;

DMSO-*d*₆) 1.08 (3 H, t, *J* 7.2, CH₂CH₃), 1.46-1.88 (6 H, m, 2 x CH₂ and NH₂), 2.63 (2 H, t, *J* 6.8, CH₂), 3.16-3.29 (2 H, m, CH₂CH₃), 3.40-3.52 (2 H, m, CH₂), 4.10-4.15 (1 H, m, C^{3'}H), 4.30 (1 H, d, *J* 1.3, C^{4'}H), 4.53-4.62 (1 H, m, C^{2'}H), 5.96 (1 H, d, *J* 7.7, C^{1'}H), 8.05 (1 H, br s, NH), 8.27 (1 H, s, adenine CH), 8.39 (1 H, s, adenine CH), 8.95 (1 H, t, *J* 5.6, amide NH); *m/z* (ES+) 380 (MH⁺).

Synthesis of fluorescent ligand, compound of formula I

ABEA-BY630 (3): ABEA 6 (5.74 mg, 15.1 μ mmol) was dissolved in *N,N*-DMF (1 cm³) under an inert atmosphere and with the exclusion of light. A solution of Bodipy 630/650-X-succinimidyl ester (Molecular Probes) (5.0 mg, 7.55 μ mmol, 1 cm³ *N,N*-DMF) was added and the reaction stirred for 4 h. The solution was evaporated and the crude product purified by preparative layer chromatography (10 % MeOH-DCM) to give the title compound 7 (3) (5.24 mg, 75%) as a purple powder; *m/z* (ES+) found 947.37 (C₄₅H₅₁BF₂N₁₀O₇SNa requires 947.36).

15




ABEA-BY630


3. NECA - C⁵ - BODIPY 630/650 (APEA-BY630) (3a)

20

This compound was synthesised using the method of Scheme 3 as described for Compound (3), with use of linker precursor of formula H₂N(CH₂)₅NHCOOCH₂Ph:



5 APEA-BY630 was obtained having the formula:




R_t 8.6 min (30-100% v/v B, 25 min)

10

4. NECA-PEG⁸- BODIPY 630/650 (ABIPEA-BY630) (3b)

This compound was synthesised using the method of Scheme 3 as described for Compound (3), wherein intermediates 1 to 3 below are analogues of structures 4 to 7 15 respectively shown in Scheme 3, with use of linker precursor of formula H₂N((CH₂)₂O)₂(CH₂)₂NH COOCH₂Ph:




*N*⁶-(8-Benzylloxycarbonylamino-3,6-dioxaoctyl)-5'-ethylamino-2',3'-isopropylidene-5'-oxo-5'-deoxyadenosine 1: δ_H (400 MHz; CDCl₃) 0.88 (3H, t *J* 7.3, Et CH₃), 1.38 (3H, s, acetonide CH₃), 1.62 (3H, s, acetonide CH₃), 3.03-3.16 (2H, m, Et CH₂), 3.40-3.93 (14H, m, 6 x linker methylenes, C³'H, C⁴'H), 4.67 (1H, s, C²'H), 5.11 (2H, s, benzyl CH₂), 5.32 (1H, s, C¹'H), 5.80 (1H, br s, carbamate NH), 6.55 (1H, br s, C⁶-NH), 7.02 (1H, br s, amide NH), 7.28-7.37 (5H, m, aromatic CH), 7.64 (1H, br s, adenine CH), 8.29 (1H, s, adenine CH).

*N*⁶-(8-Benzylloxycarbonylamino-3,6-dioxaoctyl)-5'-ethylamino-5'-oxo-5'-deoxyadenosine 2: δ_H (400 MHz; DMSO-*d*₆) 1.08 (3H, t *J* 7.2, Et CH₃), 3.12-3.17 (2H, m, linker CH₂), 3.18-3.25 (2H, m, Et CH₂), 3.41 (2H, t *J* 6.0, linker CH₂), 3.49-3.54 (4H, m, 2 x linker CH₂), 3.57-3.67 (4H, m, 2 x linker CH₂), 4.14 (1H, br m, C³'H), 4.31 (1H, d *J* 1.5, C⁴'H), 4.58-4.63 (1H, m, C²'H), 5.00 (2H, s, benzyl CH₂), 5.54 (1H, d *J* 6.4, C²'-OH), 5.74 (1H, d *J* 4.1, C³'-OH), 5.97 (1H, d *J* 7.6, C¹'H), 7.25-7.36 (6H, m, aromatic CH and carbamate NH), 7.85 (1H, br s, C⁶-NH), 8.28 (1H, br s, adenine CH), 8.40 (1H, s, adenine CH), 8.87 (1H, t *J* 5.6, amide NH).

*N*⁶-(8-Amino-3,6-dioxaoctyl)-5'-ethylamino-5'-oxo-5'-deoxyadenosine 3: δ_H (400 MHz; DMSO-*d*₆) 1.05 (3H, t *J* 7.1, Et CH₃), 1.86 (2H, br s, -NH₂), 2.71-2.80 (2H, m, linker CH₂), 3.17-3.26 (2H, m, Et CH₂), 3.41-73 (10H, m, 5 x linker CH₂), 4.15 (1H, br m, C³'H), 4.34 (1H, s, C⁴'H), 4.47-4.54 (1H, m, C²'H), 5.95 (2H, br s, C²'-OH, C³'-OH), 6.01 (1H, d *J* 7.5, C¹'H), 7.92 (1H, br s, C⁶-NH), 8.31 (1H, br s, adenine CH), 8.44 (1H, s, adenine CH), 8.95 (1H, t *J* 5.6, amide NH).

25 ABIPEA-BY630 was obtained having the formula:



TOF ES+ found 985.3993 (C₄₇H₅₆BF₂N₁₀O₉S requires 985.4013)

R_t 8.3 min (35-100% v/v B, 25 min)


5

Example A3 –Synthesis of β-Adrenoceptor agonists

1. Salmeterol-BODIPY 630/650 (4) and Derivative-Salmeterol-BODIPY 630/650 (4a)


10

Salmeterol is linked to fluorophore via two different linking sites, in the following syntheses



15 In a first approach, a linker is substituted onto the salmeterol side-chain through which the fluorophore is subsequently attached. In the second approach the native alkyl side-chain of salmeterol is replaced with a linker and fluorophore. In this case, according to the invention, retention of binding, fluorescence and activity are

uncertain and must therefore be verified and information provided with the fluorescent ligand, to provide a useful compound.




Scheme 4

5


Reagents and conditions: (i) (a) HCHO, HCl_(aq), dioxane, 60°C (b) 2,2-Dimethoxypropane, TsOH. (ii) Me₃Si, NaH, THF. (iii) (a) BocNH(CH₂)_nNH₂, EtOH, (b) HCl, Et₂O. (iv) BODIPY 630/650-X-SE, DMF, RT. (v) (a) Z_L'Y_L'-L-Y_LP_L, EtOH, (b) HCl, Et₂O, Z_L'Y_L'-L-Y_LP_L is

10



and results in compound 4a


15




5 All of the following molecules rely upon the synthesis of the same two linker moieties as shown in Scheme 4 and described above, (where the hydrocarbon chain length can be easily varied, or altered chemically to *e.g.* an ethylene glycol structure to improve solubility).

2. Clenbuterol-BODIPY 630/650 (9)

10



15





Example A4 –Synthesis of β -Adrenoceptor antagonists



All of the following molecules rely upon the synthesis of the same two linker moieties as shown in Scheme 4 and described in Example A3, (where the 5 hydrocarbon chain length can be easily varied, or altered chemically to *e.g.* an ethylene glycol structure to improve solubility).

1. CGP 12177-BODIPY 630/650 (5) 2. Propranolol-BODIPY 630/650 (6)

10



3. ICI118551-BODIPY 630/650(7) 4. Alprenolol-BODIPY 630/650(8)



15 B. PHARMACOLOGY

Example B1 – Binding of adenosine based fluorescent A₁receptor antagonists

1. XAC-BY630 (1)

20

The adenosine-A₁ receptor (A₁-AR) is a G-protein coupled receptor which is found in a variety of tissues including brain, heart, adipose tissue and muscle. By conjugating the A₁-AR antagonist xanthine amine cogener (XAC) to the fluorophore BODIPY®-630/650 (BY630), we have synthesised a fluorescent A₁-AR ligand,
5 XAC-BY630, to allow visualisation of this receptor in living cells.

[³H]DPCPX binding alongside cyclic AMP and inositol phosphate accumulation assays were performed on CHO-A1 cells expressing the human A1-receptor. Images were acquired using a Zeiss LSM510 confocal microscope using CHO-A1 cells
10 grown to 50% confluence on 8-well Labtek™ plates in Dulbecco's Modification of Eagle's Medium:Ham's F12 containing 5% foetal calf serum and 2mM glutamine. Cells were washed twice with HEPES-buffered saline prior to incubation at 22°C with compounds as indicated.

15 Spectroscopic analysis of XAC-BY630 and BY630 itself showed that their peak excitation (630, 632nm, respectively) and emission wavelengths (650, 653nm) were not substantially different. [³H]DPCPX binding studies on CHO-A1 cell membranes showed that XAC-BY630 had a lower affinity for the A₁-AR than XAC (pK_i=7.79±0.13 and 6.82±0.11, XAC and XAC-BY630, respectively,
20 mean±s.e.mean, n=4). XAC-BY630 also behaved as a competitive A₁-AR antagonist at both 5'-N-ethylcarboxamidoadenosine-mediated inhibition of cAMP production (apparent pK_B=6.98±0.15 vs. 8.06±0.24 for XAC, n=3) and stimulation of inositol phosphate production (apparent pK_B=6.26±0.20 vs. 7.46±0.08 for XAC, n=4). Confocal imaging showed that XAC-BY630 bound to membrane-localised
25 A₁-ARs in a time- and concentration-dependent manner. Binding of XAC-BY630 (25-250nM) was detected after 5 min, and was predominantly located at the membrane after a 30 min. incubation. Membrane binding of XAC-BY630 was receptor-specific, since a 30 min pre-incubation with DPCPX (10⁻⁸-10⁻⁶M) caused a concentration-dependent inhibition of membrane binding (30 min, 50nM).

These studies indicate that XAC-BY630 is a functional A₁-AR antagonist with moderate affinity which could be used to visualise the A₁-AR in primary tissue and cell lines.

5 Fluorescence Correlation Spectroscopy (FCS).

FCS is a non-invasive technique which measures fluctuations in fluorescence intensity in a confocal volume of $<10^{-15}$ l. Statistical analysis of these fluctuations gives information about the speed of diffusion (i.e. mass) and concentration of the

10 fluorescent molecules present. Thus free ligand (fast diffusing) and bound ligand (slow diffusing) can be quantified simultaneously on a single cell. We have used FCS to measure binding of the fluorescent ligand, xanthine amine cogener-BODIPY[®]630/650 (XAC-BY630) to the human adenosine A₁ receptor (A₁-AR).

15 CHO cells expressing either the human A₁-AR or an A₁-AR-Topaz fusion were cultured on glass-bottomed 8-well plates and prepared for live cell measurement. FCS measurements were made using a Zeiss Confocor 2, fitted with an Axiocam CCD camera for x-y positioning. Cells were incubated with ligands at 22°C for the times indicated and the confocal volume was positioned on the upper membrane.

20 Data were collected for 2x30s, following a 15s pre-bleach and analysed using a multi-parameter equation using Zeiss AIM software.

Initially, the diffusion characteristics of the A₁-AR-Topaz fusion protein (A₁-AR-Tpz) were determined in CHO-A1Tpz cells. Autocorrelation analysis showed the

25 diffusion time (τ_D) for the A₁-AR was 15.0 ± 0.9 ms (mean \pm s.e.mean, n=84). A second component ($\tau_D=118 \pm 14$ μs) was also seen, probably caused by an optical event within the fluorophore ("blinking"). FCS analysis of XAC-BY630 in buffer showed a single component diffusion ($\tau_D=60 \pm 2$ μs, n=10). On the upper membrane of CHO-A1 cells incubated with XAC-BY630 (1-40nM, 10-60 min, n=71), two

30 further slow-diffusing species were detected in addition to free ligand. The first component had a similar diffusion time ($\tau_{DI}=17.4 \pm 1.1$ ms; 69/71 cells) to that seen

for A₁-AR-Tpz, suggesting that it is receptor-bound ligand. The second was a very slow diffusing component ($\tau_{D2}=345\pm41$ ms, 61/71 cells). Following preincubation with 8-cyclopentyl-1,3-dipropyl xanthine (DPCPX) (1 μ M, 30 min), τ_{D2} was present in 30/31 cells, suggesting this component is non-specific binding. However, the τ_{D1} component was present in only 17/31 cells. In addition, in cells exposed to 15nM XAC-BY630 for 30 min the amount of τ_{D1} component was reduced from 51.8 \pm 14.9 to 13.6 \pm 5.4 receptors/ μ m² by DPCPX (n=8 and 4, respectively, Student's t-test, P<0.05), further suggesting this component is A₁-AR bound ligand.

10 We have used FCS to quantify binding to the A₁-AR and measure receptor diffusion in single live cells. Further development allows quantitative receptor-ligand binding of the endogenous A₁-AR in acutely dispersed cells.

15 These studies indicate that XAC-BY630 is a functional A₁-AR antagonist with moderate affinity which could be used to visualise and measure binding to the A₁-AR, in primary tissue and cell lines.

Example B2—Binding of NECA based fluorescent A₁-receptor agonists

20 **2. BY630-ABEA (3)**

Functional studies were performed in CHO-K1 cells expressing both the human A₁-AR and a c-fos-pGL3 reporter vector (CHO-A1fos cells). Cells were incubated for 24h in serum-free DMEM/F-12 media, then stimulated with agonist for 5h, in some cases following 30 min incubation with 8-cyclopentyl-1,3-dipropylxanthine (DPCPX). Luciferase expression was quantified using a Luclite® kit according to manufacturer's instructions. Live cell confocal imaging was carried out on CHO-A1 cells or CHO cells expressing the A₁-AR tagged on the C-terminus with a green fluorescent protein (CHO-A1Tpz).

30

In CHO-A1fos cells, both BY630-ABEA and the A₁-AR agonist *N*⁶-cyclopentyl adenosine (CPA) stimulated luciferase expression in a dose-dependent manner

(pEC₅₀'s of 7.01±0.04 (n=6) and 6.76±0.18 (n=5) for CPA and BY630-ABEA, respectively, mean±s.e.mean). Stimulation was mediated by the A₁-AR receptor, since the concentration response curves were shifted to the right in a competitive manner by 10nM DPCPX, yielding pK_d values of 8.72±0.03 and 9.05±0.10 vs. CPA

5 and BY630-ABEA, respectively (n=3). A higher dose of DPCPX (100nM), gave a pK_d of 8.62±0.02 for CPA stimulation, but completely blocked the response to BY630-ABEA (n=3). For receptor visualisation, CHO-A₁ cells were incubated with 100nM BY630-ABEA for up to 60min. Binding of ligand to the membrane was detectable after 5 min, and was substantial after 30 min (n=3). Binding was to the

10 A₁-AR, since it was substantially reduced by preincubation with DPCPX (1μM, 30 min). In addition, experiments in CHO-A1Tpz cells, showed co-localisation of ligand fluorescence at the membrane with that from the fluorescently tagged A₁-AR.

15 Results are shown in Figure 1 which shows images taken from confocal microscopy imaging of a) fluorescence derived from ligand binding of a fluorescent ligand of the invention to CHO cells observed at the red channel, b) fluorescence derived from green fluorescent protein expressed by CHO cells indicating receptor locations observed via the green channel and c) overlaid images from a) and b) showing overlap of fluorescence and therefore confirming ligand binding is specific to

20 receptors.

25 In conclusion, we have succeeded in synthesising a novel fluorescent agonist ligand for the human A₁-AR. This ligand will be useful in monitoring the localisation of the endogenous A₁-AR receptor in both acutely dispersed cells and cell lines.

C. LIGANDS ASSOCIATED WITH PHARMACOLOGICAL DATA

Example C1 – Data sheets for library / catalogue compound comprising adenosine based fluorescent A₁-receptor antagonists

30

1. XAC-BY630 (1)

Characterisation: Fluorescent adenosine A₁-receptor antagonist.

Synthesis and analysis: see A1 above.

Storage-20°C (dark)

5

Spectral Properties:

Excitation Max 638nm

Emission Max 655nm

10 Fluorescence Lifetime 4.2 ns

Emission quantum yield 0.33

Pharmacology:

15 CHO-cells expressing human adenosine A₁-receptor:

Inhibition of ³H-DPCPX binding (membranes) pK_B = - 6.82 + 0.11

Inhibition of ³H-DPCPX binding (whole cells) pK_B = -6.9

Antagonism of NECA-stimulated cAMP accumulation pK_I = -6.98 + 0.15

20 Antagonism of NECA-stimulated inositol phosphate accumulation pK_I = -6.26 + 0.20

Imaging:

25 Picture of XAC-BY630/650 binding to CHO-A1 cells and CHO-A1-GFP cells
Also pictures showing displacement of binding by non-fluorescent antagonist
DPCPX.

Example D LIBRARY WITH DIFFERENT FLUORESCENTLY TAGGED

30 **LIGANDS**

D1 A library is assembled comprising 3 fluorescent ligands each ligand comprising ABIPEA fluorescently tagged with a fluorophore providing different fluorescence characteristics selected from BODIPY 630/650-X-SE, EvoBlue 30 SE, BODIPY FL ethylene diamine etc.

5 Fluorescently tagged ligands are obtained by the process of the invention as hereinbefore defined.

The library includes data sheets (C. above) for each ligand.

D2 An alternative library is assembled comprising 2 fluorescent ligands
10 comprising adenosine and ABIPEA as herein before referred, each were divided into 3 samples and modified by incorporation of a linker of varying carbon chain length from C₃₋₆, whereby the compounds of formula IV comprised J_L is amine, L is (CH₂)₃₋₆ and Y_L is amine. The compounds were reacted with fluorophore providing different fluorescence characteristics selected from EvoBlue 30 SE and BODIPY 630/650 X-
15 SE.

Fluorescently tagged ligands are obtained by the process of the invention as hereinbefore defined.

The library includes data sheets (C. above) for each ligand.

20 **D3** An alternative library is assembled comprising 3 tagged ligands each ligand comprising ABIPEA tagged with a selection of tags as known in the art, including one tagged with a fluorophore.

The library includes data sheets (C. above) for each ligand.

25 The libraries are useful for conducting binding studies as known in the art for a desired fluorescent ligand having the desired fluorophore or for a selection of fluorescent ligands or for a selection of ligands one of which comprises a desired fluorophore.

30 A library was then selected for screening for binding at a desired receptor and a fluorescent ligand was selected which gave optimum pharmacology for the desired

receptor. Choice of the library to be screened is facilitated by the rational design of the library which provides the required analogues to generate a positive selection.